UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2017~~2018

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-37799

Tactile Systems Technology, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware		41-1801204
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

1331 Tyler Street NE, Suite 200 Minneapolis, Minnesota		55413
(Address of Principal Executive Offices)		(Zip Code)

(612) 355-5100

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☐		Accelerated filer	☐☒

Non-accelerated filer	☒☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐

Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 03, 2017~~August 3, 2018 there were ~~17,701,786~~18,331,393 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents

Forward-Looking Information

All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Quarterly Report on Form 10-Q. Forward-looking statements may include, among other things, statements relating to:

our expectations regarding the potential market size and widespread adoption of our products;

our ability to increase awareness of lymphedema and chronic venous insufficiency and to demonstrate the clinical and economic benefits of our solutions to clinicians and patients;

developments and projections relating to our competitors or our industry;

the expected growth in our business and our organization, including outside of the United States;

our ability to achieve and maintain adequate levels of coverage or reimbursement for our products and the effect of changes to the level of Medicare coverage;

our financial performance, our estimates of our expenses, future revenues, capital requirements and our needs for, or ability to obtain, additional financing;

our ability to retain and recruit key personnel, including the continued development and expansion of our sales and marketing organization;

our ability to obtain an adequate supply of components for our products from our ~~third party~~third-party suppliers;

our ability to obtain and maintain intellectual property protection for our products or avoid claims of infringement;

our ability to identify and develop new products;

our compliance with extensive government regulation; and

the volatility of our stock ~~price; and~~

~~our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.~~price.

You should read the matters described in "Risk Factors" and the other cautionary statements made in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 and in this Quarterly Report on Form 10-Q. We cannot assure you that the forward-looking statements in this report will prove to be accurate and therefore you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. You are urged to carefully review and consider the various disclosures made by us in this report and in other filings with the Securities and Exchange Commission (the “SEC”) that advise of the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Tactile Systems Technology, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)


(Unaudited)
	September 30,		December 31,		June 30,		December 31,
(In thousands, except share and per share data)	2017		2016		2018		2017
Assets
Current assets
Cash and cash equivalents	$	19,653	$	30,701	$	17,320	$	23,968
Marketable securities		21,993		10,994		23,802		19,944
Accounts receivable, net		14,579		15,003		17,529		17,623
Inventories		9,784		6,554		16,437		11,040
Income taxes receivable		4,768		—		5,205		2,119
Prepaid expenses		932		981
Prepaid expenses and other current assets						947		2,178
Total current assets		71,709		64,233		81,240		76,872
Property and equipment, net		3,353		1,563		4,012		3,776
Other assets
Patent costs, net		2,251		2,394
Intangible assets, net						2,984		2,218
Medicare accounts receivable, long-term		2,771		2,823		1,648		2,718
Deferred income taxes		2,797		2,785		2,648		2,662
Other non-current assets		201		137		201		201
Total other assets		8,020		8,139		7,481		7,799
Total assets	$	83,082	$	73,935	$	92,733	$	88,447

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	5,485	$	5,018	$	4,649	$	4,253
Accrued payroll and related taxes		5,880		6,692		5,520		6,706
Accrued expenses		2,357		1,193		2,033		2,598
Future product royalties		26		67		9		17
Income taxes payable		—		823
Other current liabilities		218		—		316		945
Total current liabilities		13,966		13,793		12,527		14,519
Long-term liabilities
Accrued warranty reserve, long-term		643		503		1,437		1,141
Total liabilities		14,609		14,296		13,964		15,660

Commitments and Contingencies (see Note 8)

Stockholders’ equity
Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2017 and December 31, 2016		—		—
Common stock, $0.001 par value, 300,000,000 shares authorized; 17,677,078 shares issued and 17,650,992 shares outstanding as of September 30, 2017; 16,833,737 shares issued and outstanding as of December 31, 2016		18		17
Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of June 30, 2018 and December 31, 2017						—		—
Common stock, $0.001 par value, 300,000,000 shares authorized; 18,313,061 shares issued and 18,286,975 shares outstanding as of June 30, 2018; 17,872,465 shares issued and 17,846,379 shares outstanding as of December 31, 2017						18		18
Additional paid-in capital		68,114		62,406		73,678		70,224
Retained earnings (accumulated deficit)		852		(2,773)
Retained earnings						5,604		3,082
Accumulated other comprehensive loss		(18)		(11)		(38)		(44)
Less: treasury stock, at cost — 26,086 shares as of September 30, 2017		(493)		—
Less: treasury stock, at cost — 26,086 shares as of June 30, 2018 and December 31, 2017						(493)		(493)
Total stockholders’ equity		68,473		59,639		78,769		72,787
Total liabilities and stockholders’ equity	$	83,082	$	73,935	$	92,733	$	88,447

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Tactile Systems Technology, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
(In thousands, except share and per share data)	2017		2016		2017		2016		2018		2017		2018		2017
Revenues, net	$	28,283	$	22,635	$	74,397	$	56,064	$	34,133	$	26,264	$	60,981	$	46,114
Cost of goods sold		7,528		6,282		20,186		15,417		9,610		7,034		16,919		12,658
Gross profit		20,755		16,353		54,211		40,647		24,523		19,230		44,062		33,456
Operating expenses
Sales and marketing		10,915		8,979		31,726		23,858		14,452		10,645		27,009		20,811
Research and development		1,116		1,285		3,699		3,314		1,289		1,465		2,726		2,583
Reimbursement, general and administrative		7,551		5,115		19,815		12,495		7,471		6,390		14,843		12,264
Total operating expenses		19,582		15,379		55,240		39,667		23,212		18,500		44,578		35,658
Income (loss) from operations		1,173		974		(1,029)		980		1,311		730		(516)		(2,202)
Other income		85		10		204		20		132		64		223		119
Income (loss) before income taxes		1,258		984		(825)		1,000		1,443		794		(293)		(2,083)
Income tax (benefit) expense		(84)		492		(4,450)		500
Income tax benefit										(1,129)		(2,993)		(2,815)		(4,366)
Net income		1,342		492		3,625		500	$	2,572	$	3,787	$	2,522	$	2,283
Convertible preferred stock dividends		—		224		—		1,247
Allocation of undistributed earnings to preferred stockholders		—		99		—		—
Net income (loss) attributable to common stockholders	$	1,342	$	169	$	3,625	$	(747)
Net income (loss) per common share attributable to common stockholders
Net income per common share
Basic	$	0.08	$	0.01	$	0.21	$	(0.12)	$	0.14	$	0.22	$	0.14	$	0.13
Diluted	$	0.07	$	0.01	$	0.19	$	(0.12)	$	0.13	$	0.20	$	0.13	$	0.12
Weighted-average common shares used to compute net income (loss) per common share attributable to common stockholders
Weighted-average common shares used to compute net income per common share
Basic		17,603,293		12,253,877		17,222,072		6,317,875		18,155,543		17,176,386		18,076,546		17,028,237
Diluted		19,083,975		13,982,799		18,818,609		6,317,875		19,313,156		18,814,565		19,204,100		18,713,421

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Tactile Systems Technology, Inc.

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
(In thousands)	2017		2016		2017		2016		2018		2017		2018		2017
Net income	$	1,342	$	492	$	3,625	$	500	$	2,572	$	3,787	$	2,522	$	2,283
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities		3		—		(18)		—
Unrealized gain (loss) on marketable securities										26		(8)		19		(21)
Income tax related to items of other comprehensive income (loss)		(1)		—		11		—		(14)		6		(13)		12
Total other comprehensive income (loss)		2		—		(7)		—		12		(2)		6		(9)
Comprehensive income	$	1,344	$	492	$	3,618	$	500	$	2,584	$	3,785	$	2,528	$	2,274

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Tactile Systems Technology, Inc.

Condensed Consolidated Statements of Stockholders’ Equity ~~(Deficit)~~

(Unaudited)

Retained

Accumulated

Series B Preferred Stock

Series A Preferred Stock

Common Stock

Additional

Earnings

Other

Paid-In

(Accumulated

Comprehensive

Treasury

(In thousands, except share data)

Shares

Amount

Shares

Amount

Shares

Par Value

Capital

Deficit)

Loss

Stock

Total

Balances, December 31, 2015

2,733,468

$
12,599

3,061,488

$
20,328

3,222,902

$
3

$
—

$
(5,652)

$
—

$
—

$
(5,649)

Stock-based compensation

—

—

—

—

—

—

902

—

—

—

902

Exercise of common stock options and warrants

—

—

—

—

234,135

1

223

—

—

—

224

Preferred stock dividends

—

436

—

811

—

—

(1,247)

—

—

—

(1,247)

Sale of common stock from initial public offering, net of offering expenses

—

—

—

—

4,120,000

4

35,378

—

—

—

35,382

Preferred stock dividends paid in cash

—

—

—

(8,207)

—

—

—

—

—

—

—

Common stock issued in lieu of series B preferred stock dividend

—

—

—

—

956,842

1

(1)

—

—

—

—

Conversion of series B preferred stock to common stock

(2,733,468)

(13,035)

—

—

2,733,468

3

13,032

—

—

—

13,035

Conversion of series A preferred stock to common stock

—

—

(3,061,488)

(12,932)

3,190,985

3

12,929

—

—

—

12,932

Common stock issued for series A & B preferred stock liquidation preference

—

—

—

—

2,354,323

2

(2)

—

—

—

—

Comprehensive income for the period

—

—

—

—

—

—

—

500

—

—

500

Balances, September 30, 2016

—

$
—

—

$
—

16,812,655

$
17

$
61,214

$
(5,152)

$
—

$
—

$
56,079

Balances, December 31, 2016

—

$
—

—

$
—

16,833,737

$
17

$
62,406

$
(2,773)

$
(11)

$
—

$
59,639

Stock-based compensation

—

—

—

—

—

—

3,104

—

—

—

3,104

Exercise of common stock options and warrants and vesting of restricted stock units

—

—

—

—

583,360

1

672

—

—

—

673

Taxes paid for net share settlement of restricted stock units

—

—

—

—

—

—

(278)

—

—

—

(278)

Common shares issued for employee stock purchase plan

—

—

—

—

259,981

—

2,210

—

—

—

2,210

Shares repurchased to cover taxes from restricted stock award vesting

—

—

—

—

(26,086)

—

—

—

—

(493)

(493)

Comprehensive income for the period

—

—

—

—

—

—

—

3,625

(7)

—

3,618

Balances, September 30, 2017

—

$
—

—

$
—

17,650,992

$
18

$
68,114

$
852

$
(18)

$
(493)

$
68,473


						Retained		Accumulated
				Additional		Earnings		Other
	Common Stock			Paid-In		(Accumulated		Comprehensive		Treasury
(In thousands, except share data)	Shares	Par Value		Capital		Deficit)		Loss		Stock		Total
Balances, December 31, 2016	16,833,737	$	17	$	62,406	$	(2,773)	$	(11)	$	—	$	59,639
Stock-based compensation	—		—		2,137		—		—		—		2,137
Exercise of common stock options and warrants and vesting of restricted stock units	473,740		1		578		—		—		—		579
Taxes paid for net share settlement of restricted stock units	—		—		(153)		—		—		—		(153)
Common shares issued for employee stock purchase plan	259,981		—		2,210		—		—		—		2,210
Shares repurchased to cover taxes from restricted stock award vesting	(26,087)		—		—		—		—		(493)		(493)
Comprehensive income for the period	—		—		—		2,283		(9)		—		2,274
Balances, June 30, 2017	17,541,371	$	18	$	67,178	$	(490)	$	(20)	$	(493)	$	66,193

Balances, December 31, 2017	17,846,379		18		70,224		3,082		(44)		(493)		72,787
Stock-based compensation	—		—		3,258		—		—		—		3,258
Exercise of common stock options and vesting of restricted stock units	377,018		—		571		—		—		—		571
Taxes paid for net share settlement of restricted stock units	—		—		(1,791)		—		—		—		(1,791)
Common shares issued for employee stock purchase plan	63,578		—		1,416		—		—		—		1,416
Comprehensive income for the period	—		—		—		2,522		6		—		2,528
Balances, June 30, 2018	18,286,975	$	18	$	73,678	$	5,604	$	(38)	$	(493)	$	78,769

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Tactile Systems Technology, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended				Six Months Ended
	September 30,				June 30,
(In thousands)	2017		2016		2018		2017
Cash flows from operating activities
Net income	$	3,625	$	500	$	2,522	$	2,283
Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net income to net cash used in operating activities
Depreciation and amortization		1,073		675		1,687		664
Stock-based compensation expense		3,104		859		3,258		2,137
Change in allowance for doubtful accounts		(36)		465		250		(296)
Loss on disposal of equipment						3		—
Changes in assets and liabilities:
Accounts receivable		460		665		(156)		2,389
Inventories		(3,821)		(467)		(5,397)		(3,077)
Income taxes		(5,591)		(732)
Income taxes receivable						(3,086)		(5,263)
Prepaid expenses and other assets		130		499		231		354
Medicare accounts receivable – long-term		52		395		1,070		(138)
Accounts payable		370		1,695		309		851
Accrued payroll and related taxes		(812)		895		(1,186)		(3,574)
Accrued expenses		1,520		(387)
Accrued expenses and other liabilities						(896)		688
Future product royalties		(41)		(726)		(8)		(33)
Net cash provided by operating activities		33		4,336
Net cash used in operating activities						(1,399)		(3,015)
Cash flows from investing activities
Proceeds from sales of marketable securities		1,000		—
Proceeds from sales and maturities of marketable securities						9,000		1,000
Purchases of marketable securities		(12,051)		—		(11,844)		(11,049)
Purchases of property and equipment		(1,953)		(518)		(1,700)		(1,516)
Patent costs		(44)		(24)
Intangible asset costs						(901)		(23)
Other investments		(145)		—		—		(145)
Net cash used in investing activities		(13,193)		(542)		(5,445)		(11,733)
Cash flows from financing activities
Taxes paid for net share settlement of restricted stock units		(278)		—		(1,791)		(153)
Proceeds from exercise of common stock options and warrants		673		224		571		579
Proceeds from the issuance of common stock from the ESPP		2,210		—
Proceeds from the issuance of common stock from the employee stock purchase plan						1,416		2,210
Shares repurchased to cover taxes from restricted stock award vesting		(493)		—		—		(493)
Dividends paid on preferred stock		—		(8,207)
Proceeds from IPO		—		41,200
Fees paid for IPO		—		(4,777)
Net cash provided by financing activities		2,112		28,440		196		2,143
Net change in cash and cash equivalents		(11,048)		32,234		(6,648)		(12,605)
Cash and cash equivalents – beginning of period		30,701		7,060		23,968		30,701
Cash and cash equivalents – end of period	$	19,653	$	39,294	$	17,320	$	18,096
Supplemental cash flow disclosure
Cash paid for interest	$	1	$	—
Cash paid for taxes	$	923	$	1,261	$	436	$	898
Non-cash investing activities:
Acquisition of assets included in accounts payable	$	97	$	37
Capital expenditures incurred but not yet paid					$	87	$	294

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Tactile Systems Technology, Inc.

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

Note 1. Nature of ~~Operations~~Business and ~~Basis of Presentation~~

~~Nature of~~ Operations

Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is the sole manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition, and the Actitouch system, a medical device used to treat venous leg ulcers and chronic venous insufficiency. We provide our products for ~~a patient’s~~ use in the home and sell them through vascular, wound and lymphedema clinics throughout the United ~~States through referrals from clinicians diagnosing and treating lymphatic and vascular disorders.~~States. We do business as “Tactile Medical.”

We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as “Tactile Medical.”

On August 2, 2016 we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $10.00 per share. We received net proceeds from the initial public offering of approximately $35.4 million, after deducting underwriting discounts and approximately $2.9 million of transaction expenses. In connection with the closing of the initial public offering, all of our outstanding redeemable convertible preferred stock automatically converted to common stock on August 2, 2016. At August 2, 2016, we did not have any redeemable convertible preferred stock issued or outstanding.

Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher sales in the third and fourth quarters as a result of patients having paid their annual insurance deductibles in full, thereby reducing their out-of-pocket costs for our products, and because patients often spend the remaining balances in their healthcare flexible spending accounts at that time. This seasonality applies only to purchases of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid, or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year or do not have plans that include patient deductibles for purchases of our products.

Note 2. Basis of Presentation

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. We have reclassified certain prior year amounts to conform to the current year’s presentation.

The results for the ~~three and nine~~six months ended ~~September~~June 30, ~~2017~~2018 are not necessarily indicative of results to be expected for the year ending December 31, ~~2017,~~2018, or for any other interim period or for any future year. Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher sales in the third and fourth quarters as a result of patients having paid their annual insurance deductibles in full, thereby reducing their out-of-pocket costs for our products, and because patients often spend the remaining balances in their flexible spending accounts at that time. This seasonality applies only to purchases of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid, or Veterans Administration hospitals, as those payers do not have plans that include patient deductibles for purchases of our products. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017.

In connection with preparing for our initial public offering, our board of directors and stockholders approved a 1-for-2.820044 reverse stock split of our capital stock. The reverse stock split became effective in June 2016. All share and per share amounts in these condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.

~~Table of Contents~~

~~Basis~~Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc.~~, after elimination~~ All intercompany balances and transactions have been eliminated in consolidation.

Table of ~~intercompany accounts and transactions.~~Contents

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Comprehensive Income

Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on available-for-sale marketable securities.

JOBS Act Accounting Election

As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), we currently are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies. However, as of the last business day of our second fiscal quarter of 2018, the market value of our common stock that was held by non-affiliates exceeded $700 million, and as a result, we will no longer qualify as an emerging growth company as of December 31, 2018. Therefore, after that date, we will no longer be able to take advantage of the extended transition period for adopting new or revised accounting standards.

Note 3. Summary of Significant Accounting Policies

Significant Accounting Policies

During the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 there were no material changes in our significant accounting policies. See Note 13 - “Summary of Significant Accounting Policies” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 for information regarding our significant accounting policies.

Recent Accounting Pronouncements

We currently are an “emerging growth company” as defined by the ~~Jumpstart Our Business Startups (“JOBS”) Act of 2012.~~JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, (the “Securities Act”), for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We ~~have~~ elected to avail ourselves of this exemption and, as a result, our financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable. However, as of the last business day of our second fiscal quarter of 2018, the market value of our common stock that was held by non-affiliates exceeded $700 million, and as a result, we will no longer qualify as an emerging growth company as of December 31, 2018 and will no longer be able to take advantage of the extended transition period. Therefore, as of December 31, 2018, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” The new section ~~will replace~~replaces Section 605, “Revenue Recognition,” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards to reconcile previously differing treatment between U.S. practices and those of the rest of the world and to enhance disclosures related to disaggregated revenue information. The updated guidance iswill be effective for us for our interim and annual reporting periods ~~beginning~~ending on or after December ~~15,~~31, 2018 ~~for private companies; this effective date is applicable for us~~ due to the ~~JOBS Act exemption described above. Therefore,~~recent determination of our upcoming change in filing status. As a result, we ~~plan~~have commenced project planning for our implementation, which

Table of Contents

has included engaging an accounting firm to ~~further evaluate the timing and anticipated impact of the adoption of this updated guidance~~assist us. We have not yet made a determination on our ~~consolidated~~transition method, nor have we determined whether this standard will have a material impact on our financial ~~statements in future periods.~~statements.

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), which supersedes the existing guidance for lease accounting, “Leases” (Topic 840). ASU 2016-02 requires lessees to recognize a lease liability and a right-of-use asset for all leases. Lessor accounting remains largely unchanged. The amendments in this ASU ~~are~~will be effective for us for interim and annual periods beginning after December 15, ~~2019 for private companies; this effective date is applicable to us due to the JOBS Act exemption described above. Early adoption is permitted for all entities.~~2018. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial adoption, with an option to elect to use certain transition relief. ~~We plan~~Due to ~~further evaluate~~ the ~~timing and anticipated impact~~recent determination of ~~the adoption~~our upcoming change in filing status, which has accelerated our required implementation date of this ~~ASU~~standard, we have commenced project planning for our implementation. We are currently evaluating whether this standard will have a material impact on our ~~consolidated~~ financial ~~statements in future periods.~~statements.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments — Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU iswill be effective for us for interim and annual periods beginning after December 15, ~~2020, for private companies; this effective date is applicable to us due to the JOBS Act exemption described above.~~2019. Therefore, we plan to further evaluate the ~~timing and~~ anticipated impact of the adoption of this ASU on our consolidated financial statements in future periods.

~~Table of Contents~~

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) — Classification of Certain Cash Receipts and Cash Payments,” to provide clarity on how certain cash receipt and cash payment transactions are presented and classified within the statement of cash flows. The ASU iswill be effective for us for interim and annual periods beginning after December 15, ~~2018 for private companies; this effective date is applicable for us due to the JOBS Act exemption described above. Therefore, we plan to further evaluate the timing and anticipated~~2018. We do not anticipate any material impact ~~of the adoption of this ASU~~ on our consolidated financial statements in future ~~periods.~~periods as a result of the adoption of this ASU.

~~Cash~~In January 2017, the FASB issued ASU No. 2017-01 “Business Combinations (Topic 805) — Clarifying the Definition of a Business,” to revise the definition of a business and ~~Cash Equivalents~~provide new guidance to assist in the evaluation of transactions as either asset acquisitions (disposals) or business acquisitions (disposals). We currently are an “emerging growth company” as defined by the JOBS Act and this ASU will become effective for us on December 31, 2018 when we no longer qualify for that status. We have elected early adoption for interim transactions that have not previously been included in issued financial statements, which is permitted under this standard. The adoption of this standard did not have a material impact on our consolidated financial statements.

~~Cash~~Note 4. Asset Acquisition

On May 22, 2018, we acquired certain assets and ~~cash equivalents consist~~the intellectual property of ~~all cash~~Wright Therapy Products, Inc. (“WTP”) for total consideration of approximately $875,000 plus a potential earn-out. The earn-out is based on ~~hand, deposits~~certain revenue metrics over the seven-month period beginning June 30, 2018 and ~~funds invested in available-for-sale securities with original maturities~~is capitalized to intangible assets. The assets include the rights to a portfolio of ~~three months or less at~~thirty-one issued and pending patents that include intellectual property related to WTP’s pneumatic compression therapy devices and five related trademarks, as well as certain customer accounts. Due to the ~~time~~nature of ~~purchase. At September 30, 2017,~~these patents and related trademarks, as well as our ~~cash~~planned use, they have been classified as defensive intangible assets on the balance sheet. The acquisition was ~~held primarily in checking~~recorded as an asset acquisition, and ~~money market accounts.~~an allocation of the purchase price, based on relative fair value, has been completed as reflected below:


	Gross		Weighted-Average
(Dollars in thousands)	Carrying Amount		Amortization Period
Defensive intangible assets	$	787.8	7 years
Customer accounts		87.5	5 years
Total	$	875.3

Table of Contents

Note 2.5. Marketable Securities

Our investments in marketable securities, all of which have original contractual maturities of twelve to twenty-five months, are classified as available-for-sale and consist of the following:


	September 30, 2017								As of June 30, 2018
			Unrealized		Unrealized						Unrealized				Fair
(In thousands)	Cost		Gains		Losses		Fair Value		Cost		Gains		Losses		Value
U.S. government and agency obligations	$	13,000	$	1	$	33	$	12,968	$	17,863	$	—	$	41	$	17,822
Corporate debt securities		9,028		—		3		9,025
Corporate debt securities and certificates of deposit										5,990		—		10		5,980
Marketable securities	$	22,028	$	1	$	36	$	21,993	$	23,853	$	—	$	51	$	23,802


	December 31, 2016								As of December 31, 2017
			Unrealized		Unrealized						Unrealized				Fair
(In thousands)	Cost		Gains		Losses		Fair Value		Cost		Gains		Losses		Value
U.S. government and agency obligations	$	9,011	$	2	$	17	$	8,996	$	11,997	$	—	$	56	$	11,941
Corporate debt securities		2,000		—		2		1,998
Corporate debt securities and certificates of deposit										8,017		—		14		8,003
Marketable securities	$	11,011	$	2	$	19	$	10,994	$	20,014	$	—	$	70	$	19,944

~~Our investments in~~

Unrealized losses and fair value of marketable ~~debt~~ securities ~~all have contractual maturities~~aggregated by investment category and the length of ~~12 to 25 months from September 30, 2017. At September 30, 2017, marketable debt~~time the securities ~~valued at $2.0 million~~ were in ~~an unrealized gain position totaling $1,000, and marketable debt securities valued at $20.0 million were in an unrealized~~a continuous loss position ~~totaling $36,000 (all had been in an unrealized loss position for less than 12 months). At December 31, 2016, marketable debt securities valued at $4.0 million~~ were in an unrealized gain position totaling $2,000 and marketable debt securities valued at $7.0 million were in an unrealized loss position totaling $19,000 (all had been in an unrealized loss position for less than 12 months).

Net pre-tax unrealized losses for marketable debt securities of $35,000 at September 30, 2017 were recorded as a component of accumulated other comprehensive loss in stockholders' equity. Marketable debt securities valued at $1.0 million were sold during the nine months ended September 30, 2017, with no resulting gain or loss.

~~Note 3. Patent Costs, Net~~

~~Our patents, all of which are subject to amortization, are summarized~~ as follows:

As of

As of

(In thousands)

September 30, 2017

December 31, 2016

Patents

$
3,506

$
3,462

Less: accumulated amortization

(1,255)

(1,068)

Net patents

$
2,251

$
2,394


	As of June 30, 2018
	Less than 12 months				12 months or more				Total
	Fair		Unrealized		Fair		Unrealized		Fair		Unrealized
(In thousands)	Value		Losses		Value		Losses		Value		Losses
U.S. government and agency obligations	$	9,879	$	26	$	4,985	$	15	$	14,864	$	41
Corporate debt securities and certificates of deposit		4,981		9		999		1		5,980		10
Marketable securities	$	14,860	$	35	$	5,984	$	16	$	20,844	$	51


	As of December 31, 2017
	Less than 12 months				12 months or more				Total
	Fair		Unrealized		Fair		Unrealized		Fair		Unrealized
(In thousands)	Value		Losses		Value		Losses		Value		Losses
U.S. government and agency obligations	$	5,974	$	25	$	5,967	$	31	$	11,941	$	56
Corporate debt securities and certificates of deposit		7,005		13		998		1		8,003		14
Marketable securities	$	12,979	$	38	$	6,965	$	32	$	19,944	$	70

1011

Table of Contents

Note 6. Intangible Assets

Our patents and other intangible assets, all of which are subject to amortization, are summarized as follows:


		As of June 30, 2018						As of December 31, 2017
	Weighted-Average	Gross						Gross
	Amortization	Carrying		Accumulated		Net		Carrying		Accumulated		Net
(Dollars in thousands)	Period	Amount		Amortization		Amount		Amount		Amortization		Amount
Patents	8 years	$	3,540	$	1,442	$	2,098	$	3,536	$	1,318	$	2,218
Defensive intangible assets	7 years		807		10		797		—		—		—
Customer accounts	5 years		90		1		89		—		—		—
Total		$	4,437	$	1,453	$	2,984	$	3,536	$	1,318	$	2,218

Amortization expense was $0.1 million for each of the three and six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016 and $0.2 million for each of the nine months ended September 30, 2017 and 2016.~~2017. Future amortization expenses are expected as follows:


(In thousands)
2017 (October 1 - December 31)	$	62
2018		249
2018 (July 1 - December 31)			$	189
2019		249		379
2020		249		379
2021		249		379
2022				379
Thereafter		1,193		1,279
Total	$	2,251	$	2,984

Note 4.7. Accrued Expenses

Accrued expenses consisted of the following:


	As of		As of
(In thousands)	September 30, 2017		December 31, 2016		As of June 30, 2018		As of December 31, 2017
Accrued taxes					$	77	$	1,070
Warranty	$	345	$	290		665		531
Travel and business		268		308		516		453
Legal and consulting		633		275		483		317
Deferred rent		174		159		166		173
Accrued taxes		876		—
Clinical		16		45
Clinical studies						55		15
Other		45		116		71		39
Total	$	2,357	$	1,193	$	2,033	$	2,598

~~Note 5. Line of Credit — Bank~~

At December 31, 2016 we had a $2.0 million line of credit with a bank that bore interest based on the prime rate. There was no outstanding balance on the line of credit as of December 31, 2016. The line of credit expired on May 11, 2017, and there was no outstanding balance on the line as of that date.

Note 6.8. Commitments and Contingencies

Lease Obligations

In March 2008, we entered into a non-cancelable operating lease agreement for building space for our corporate headquarters that provides for monthly rent, real estate taxes and operating ~~expenses that~~expenses. This lease was subsequently extended to July 31, 2021.

In July 2016, we entered into a non-cancelable operating lease agreement for building space to accommodate the relocation of our manufacturing, quality, engineering and research and development functions. ~~The~~This lease agreement extends through November 2021 and provides for monthly rent, real estate taxes and operating expenses.

Rent expense was $0.4 million and ~~$0.2~~$0.3 million for the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively, and ~~$1.1~~$0.7 million and ~~$0.6~~$0.5 million for the ~~nine~~six months ended ~~September~~June 30, 2018 and 2017, ~~and 2016,~~ respectively.

Table of Contents

In July 2016, we entered into a fleet vehicle lease program for certain members of our field sales organization. At ~~September~~June 30, ~~2017,~~2018, we had 2617 vehicles with future lease obligations under this program.

We also have operating lease agreements for certain computer and office equipment that expire in ~~2020.~~2021. The leases provide an option to purchase the related equipment at fair market value at the end of the lease.

~~Table of Contents~~

Future base minimum lease payments for all lease obligations are expected to be as follows for the years ending December 31:


			Computer/Office		Fleet Car						Computer/Office		Fleet Vehicle
(In thousands)	Buildings		Equipment		Program		Total		Buildings		Equipment		Program		Total
2017 (October 1 - December 31)	$	174	$	15	$	5	$	194
2018		714		76		28		818
2018 (July 1 - December 31)									$	405	$	28	$	82	$	515
2019		733		39		—		772		866		51		38		955
2020		752		22		—		774		870		34		—		904
2021		526		—		—		526		592		3		—		595
2022										—						—
Thereafter		—		—		—		—		—		—		—		—
Total	$	2,899	$	152	$	33	$	3,084	$	2,733	$	116	$	120	$	2,969

Major Vendors

We had purchases from ~~three~~two major vendors that ~~collectively~~ accounted for ~~47%~~44% and ~~35%~~39% of our total purchases for the three and six months ended ~~September~~June 30, ~~2017 and 2016, respectively, and 39% and~~2018, respectively. We had purchases from three major vendors that accounted for 36% of our total purchases for each of the ~~nine~~three and six months ended ~~September~~June 30, 2017.

Purchase Commitments

We issued purchase orders in 2017 totaling $5.9 million for items that we expect to receive between August and ~~2016, respectively.~~December of 2018.

Employment Agreements

We have entered into employment agreements with certain of our officers. The agreements provide for payment of severance ranging from 9 to 15 months of then-current annualized base salary in the event of termination by us without cause or by the employee for good reason or, in the case of two of the officers, death, disability, or as a result of a qualifying termination after a change in control. The agreements also provide for payment of an amount equal to 9 to 15 months of the then-current annual target bonus in the event of termination by us without cause or by the employee for good reason, or, in the case of two of the officers, death, disability, or as a result of a qualifying termination after a change in control. In addition, the agreements provide for the vesting of certain equity compensation through the date of termination in the event of termination by us without cause or by the employee for good reason.

Retirement Plan

We maintain a 401(k) retirement plan for our employees in which eligible employees can contribute a percentage of their pre-tax compensation. We may also make discretionary contributions to the 401(k) plan. We made contributions of ~~$42,000~~$58,000 and ~~$45,000~~$48,000 for the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively, and ~~$135,00~~0$111,000 and ~~$120,000~~$93,000 for the ~~nine~~ six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively.

Note 7.9. Stockholders' Equity

We completed an initial public offering of our common stock on August 2, 2016, in which we sold 4,120,000 shares of our common stock at a public offering price of $10.00 per share. Immediately prior to the completion of the initial public offering, all then-outstanding shares of our Series A and Series B preferred stock were converted into 5,924,453 shares of our common stock. Our Series A preferred stock converted to common stock at a ratio of 1-for-1.03 and our Series B preferred stock converted to common stock at a ratio of 1-for-1. In addition, immediately prior to the completion of the initial public offering, we issued 2,354,323 additional shares of our common stock that our Series A and

Table of Contents

Series B preferred stockholders were entitled to receive in connection with the conversion of the preferred stock, and we issued 956,842 shares of our common stock to pay accrued dividends on our Series B preferred stock. We also paid $8.2 million in cumulative accrued dividends to our Series A convertible preferred stockholders in connection with the initial public offering, including $0.1 million of dividends paid to the holders of the common restricted shares.

Stock-Based Compensation

Our 2016 Equity Incentive Plan (the “2016 Plan”) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending

~~Table of Contents~~

on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expire, are cancelled, are settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Effective January 1, 2017, 841,686 shares were added to the 2016 Plan, as available for issuance thereunder, pursuant to the automatic increase feature of the 2016 Plan. Effective January 1, 2018, 892,318 shares were added to the 2016 Plan, as available for issuance thereunder, pursuant to the automatic increase feature of the 2016 Plan. As of ~~September~~June 30, ~~2017, 4,870,532~~2018, 5,230,344 shares were available for future grant pursuant to the 2016 Plan.

Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms.

We recorded stock-based compensation expense of ~~$1.0~~$1.8 million and ~~$0.7~~$1.2 million for the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively, and ~~$3.1~~$3.3 million and ~~$0.9~~$2.1 million for the ~~nine~~ six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively. This expense was allocated as follows:


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
(In thousands)	2017		2016		2017		2016		2018		2017		2018		2017
Cost of goods sold	$	4	$	33	$	102	$	71	$	69	$	49	$	109	$	98
Sales and marketing expenses		361		188		1,030		272		786		354		1,438		669
Research and development expenses		29		14		73		14		25		21		94		44
Reimbursement, general and administrative expenses		573		474		1,899		502		897		756		1,617		1,326
Total stock-based compensation expense	$	967	$	709	$	3,104	$	859	$	1,777	$	1,180	$	3,258	$	2,137

Stock Options

Stock options issued to participants other than non-employees vest over three or four years and typically have a contractual term of seven or ten years. ~~The~~Annually, stock options ~~granted on July 27, 2016 to our non-employee directors vested in full on May 9, 2017, the date of our 2017 annual meeting of stockholders. New stock options were~~are granted to our non-employee directors on ~~that date. These options~~the date of the annual meeting of stockholders and vest in full on the earlier of ~~May 9, 2018 or~~one year after the date of ~~our 2018~~grant or on the date of the next year’s annual meeting of stockholders. These options have a contractual term of seven years. ~~Our~~

Stock-based compensation expense included in our Condensed Consolidated Statements of Operations for stock options was $0.5 million and $0.3 million for the three months ended June 30, 2018 and 2017, respectively, and $1.0 million and $0.5 million for the six months ended June 30, 2018 and 2017, respectively.

At June 30, 2018, there was approximately $4.9 million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 2.8 years.

Table of Contents

Stock option activity for the ~~nine~~six months ended ~~September~~June 30, ~~2017 was~~2018 is summarized as follows:


								Weighted-		Weighted-
			Weighted Average	Weighted Average	Aggregate			Average		Average	Aggregate
	Options		Exercise Price	Remaining	Intrinsic		Options	Exercise Price		Remaining	Intrinsic
(In thousands except share, per share and years data)	Outstanding		Per Share1	Contractual Life	Value2		Outstanding	Per Share (1)		Contractual Life	Value (2)
Balance at December 31, 2016	1,856,299	$	2.69	5.5 years	$	25,467
Balance at December 31, 2017							1,487,720	$	8.41	6.2 years	$	29,611
Granted	63,066		25.69				110,521	$	35.01
Exercised	(517,283)		1.25			12,001	(265,139)	$	2.16		$	9,842
Forfeited	(50,656)		7.86				(20,851)	$	20.91
Balance at September 30, 2017	1,351,426		4.12	5.3 years		36,305
Balance at June 30, 2018							1,312,251	$	11.72	6.3 years	$	52,860

Options exercisable at September 30, 2017	1,098,882	$	2.12	4.6 years	$	31,619
Options exercisable at June 30, 2018							806,689	$	3.67	4.9 years	$	38,989

(1)

The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant.

(2)

The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.

Options exercisable of ~~1,283,036~~1,152,453 as of ~~September~~June 30, ~~2016~~2017 had a ~~weighted average~~weighted-average exercise price of ~~$1.02~~$1.92 per share.

Stock based compensation expense included in our Condensed Consolidated Statements of Operations for stock options was $0.3 million and $0.2 million for the three months ended September 30, 2017 and 2016, respectively, and $0.8 million and $0.2 million for the nine months ended September 30, 2017 and 2016, respectively.

~~Table of Contents~~

At September 30, 2017, there was approximately $1.2 million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 2.4 years.

Stock-Settled Restricted Stock Units

~~Stock-settled~~We have granted both time-based and performance-based stock-settled restricted stock units to certain participants under the 2016 Plan.

Time-based stock-settled restricted stock units granted under the 2016 Plan vest over one to three years. These awards are stock-settled with common shares. Stock-based compensation expense included in our Condensed Consolidated ~~Statement~~Statements of Operations for time-based stock-settled restricted stock units was ~~$0.6~~$0.9 million and ~~$0.3~~$0.7 million for the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively, and ~~$1.8~~$1.7 million and ~~$0.3~~$1.2 million for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively. As of ~~September~~June 30, ~~2017,~~2018, there was approximately ~~$4.5~~$6.0 million of total unrecognized pre-tax compensation expense related to outstanding time-based stock-settled restricted stock units that is expected to be recognized over a weighted-average period of ~~2.1~~2.0 years. Our time-based stock-settled restricted stock unit activity for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 was as follows:

Weighted





Average Grant

Aggregate


Units

Date Fair Value

Intrinsic

(In thousands except share and per share data)

Outstanding

Per Share

Value(1)

Balance at December 31, 2016

324,863

$
10.39

$
5,331

Granted

187,902

21.40

Vested

(75,821)

11.47

Cancelled

(35,887)

15.17

Balance at September 30, 2017

401,057

$
15.13

$
12,413

Deferred and unissued at September 30, 2017 (2)

1,912

$
21.51

$
59


		Weighted-
		Average Grant		Aggregate
	Units	Date Fair Value		Intrinsic
(In thousands except unit and per unit data)	Outstanding	Per Unit		Value (1)
Balance at December 31, 2017	441,507	$	16.38	$	12,795
Granted	86,416	$	33.70
Vested	(166,746)	$	21.96
Cancelled	(16,901)	$	20.02
Balance at June 30, 2018	344,276	$	27.72	$	17,902

Deferred and unissued at June 30, 2018 (2)	3,147	$	27.74	$	164

(1)

~~Intrinsic~~The aggregate intrinsic value of stock-settled restricted stock units outstanding was based on our closing stock price on the last trading day of the period.

(2)

For the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, there were ~~1,680~~934 restricted stock units granted to non-employee directors in lieu of their quarterly cash retainer payments. These restricted stock units were fully vested upon grant and represent the right to receive one share of common stock, per unit, upon the earlier of the directors’ termination of service as a director of ours or the occurrence of a change of control of us. These restricted stock units are included in the “Granted” line in the table above and are also included in the “Vested” line in the table above due to their being fully vested upon grant. On May 9, 2017, upon his departure from our board of directors, we issued 1,494 shares of common stock to Mr. Shroff, which represented the settlement of restricted stock units that had been previously granted to him in lieu of his quarterly director retainer payments. As of ~~September~~June 30, ~~2017,~~2018, there were ~~1,912~~3,147 outstanding restricted stock units that ~~had~~have been ~~previously~~ granted to non-employee directors in lieu of their quarterly director retainer payments. These restricted stock units are not included in the “Balance at ~~September~~June 30, ~~2017”~~2018” line in the table above ~~but listed separately~~ because they are fully vested.

Table of Contents

In February 2018, we granted 67,982 performance-based stock-settled restricted stock units (“PSUs”), which represents the target number of PSUs under these awards, to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2019. The number of PSUs earned will depend on the level at which the performance targets are achieved, and can range from 50% of target if threshold performance is achieved and up to 150% of target if maximum performance is achieved. One third of the earned PSUs will vest on the date the Compensation and Organization Committee certifies the number of PSUs earned, and the remaining two thirds of the earned PSUs will vest on the first anniversary of that certification date. All earned and vested PSUs will be settled in shares of common stock. Stock-based compensation expense included in our Condensed Consolidated Statements of Operations for PSUs was $0.2 million and $0.3 million for the three and six months ended June 30, 2018, respectively, and $0 for the same periods in 2017. As of June 30, 2018, there was approximately $1.9 million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of 2.7 years.

Employee Stock Purchase Plan

Our employee stock purchase plan (“ESPP”), which was approved by our Board of Directors on April 27, 2016 and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The plan is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The plan ~~ordinarily consists of~~provides for six-month purchase periods, beginning on May 16 and November 16 of each calendar year, but the initial purchase period began on July 27, 2016 and ended on May 15, 2017. As of May 15, 2017, 259,981 shares were purchased utilizing $2.2 million of employee contributions in the initial purchase period. year.

A total of 1.6 million shares of common stock ~~were~~was initially reserved for issuance under the ~~plan,~~ESPP, and this share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (1) 1% of the shares of our common stock outstanding on the immediately preceding December 31, (2) 500,000 shares or (3) such lesser amount as our Board of Directors may determine. Effective January 1, ~~2017, 168,337~~2018, 178,463 shares were added to the ESPP, as available for issuance thereunder, pursuant to the automatic increase feature of the plan. On May 15, 2018, 63,578 shares were purchased under the ESPP, utilizing $1.4 million of employee contributions. As of ~~September~~June 30, ~~2017, 1,508,356~~2018, 1,576,090 shares were available for future issuance under the ESPP. We recognized ~~$0.1 million and $0.5 million in~~ stock-based compensation expense ~~related to~~associated with the ESPP of $0.1 million and $0.2 million for the three ~~and nine~~ months ended ~~September~~June 30, 2018 and 2017, ~~respectively. We recognized stock based compensation expense related to the ESPP of $0.2~~respectively, and $0.3 million and $0.4 million for ~~each of~~ the ~~three and nine~~six months ended ~~September~~June 30, ~~2016.~~

~~Table of Contents~~

2018 and 2017, respectively.

Note 8.10. Income Taxes

We record our interim provision for income taxes by applying our estimated annual effective tax rate to our year-to-date pre-tax income and ~~adjust the provision~~adjusting for discrete tax items recorded in the period. Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax reporting purposes, including for depreciation and amortization, warranty and vacation accruals, ~~share-based compensation~~ and deductions related to allowances for doubtful accounts receivable and inventory reserves. Our provision for income taxes included current federal and state income tax expense, as well as deferred federal and state income tax expense.

The effective tax rate for the three months ended ~~September~~June 30, ~~2017~~2018 was ~~(6.7)%~~a benefit of 78.3%, compared to ~~50.0%~~a benefit of 376.5% for the three months ended ~~September~~June 30, ~~2016.~~2017. The primary driver of the change in ~~our~~the effective tax rate was a ~~significant increase~~decrease in the tax benefits related to tax-deductible ~~share-based~~stock-based compensation activity, combined with an increase in our pre-tax book income as compared to the same prior year period. ~~The significant~~Significant tax deductions ~~related to tax~~in both the current and prior year period included benefits with respect to the vesting of restricted stock units, exercises of non-qualified stock options, and disqualifying dispositions of incentive stock options and ESPP shares. We recorded an income tax benefit of ~~$0.~~1$1.1 million and ~~an income tax expense of $0.5~~$3.0 million for the three months ended ~~September~~June 30, 2018 and 2017, ~~and 2016,~~ respectively. The significant tax benefits in the current year period related to the share-based compensation activity resulted in an aggregate tax benefit despite the fact that we generated pre-tax income of $1.3 million for the quarter ended September 30, 2017, driving the effective tax rate for the period to a negative rate. Our provisions for income taxes included current federal and state income tax expense, as well as deferred federal and state income tax expense.

The effective tax rate for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 was ~~539.1%~~958.9%, compared to ~~50.0%~~209.7% for the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2017. The primary driver of the change in ~~our~~the effective tax rate was a ~~significant increase~~decrease in the tax benefits related to tax-deductible ~~share-based~~stock-based compensation activity, combined with a decrease in our pre-tax book loss as compared to the same prior year period. The significant tax deductions related to tax benefits with respect to the vesting of restricted stock awards and restricted stock units, exercises of non-qualified stock options, and disqualifying dispositions of incentive stock options and ESPP shares. Largely as a result of this activity, weWe recorded an income tax benefit of ~~$4.5~~$2.8 million and an income tax benefit of $4.4 million for the ~~nine~~six months ended ~~September~~June 30, 2018 and 2017, ~~compared to income tax expense~~respectively.

Table of $0.5 million for the nine months ended September 30, 2016. The tax benefit of $4.5 million in the current year period on a pre-tax loss of $0.8 million resulted in the 539.1% effective tax rate for the nine months ended September 30, 2017. Our provisions for income taxes included current federal and state income tax expense, as well as deferred federal and state income tax expense.Contents

We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the ~~more~~“more likely than ~~not~~not” threshold, the amount recognized in the condensed consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. As of ~~September~~June 30, ~~2017,~~2018 we had an unrecognized tax benefit ("UTB") with respect to state income taxes of approximately ~~$0.2 million.~~$57,000. The UTB represents ~~tax,~~taxes, interest, and penalties related to ~~unfiled~~un-filed and unpaid income taxes in ~~several~~multiple state jurisdictions. We are ~~pursuing~~continuing actions to settle these outstanding liabilities. To date, we have settled a significant portion of our outstanding liabilities ~~and reviewing compliance in all relevant~~through voluntary settlements with various state taxing authorities.

We are currently under examination by the Internal Revenue Service for our 2016 federal tax ~~jurisdictions.~~

return. We are not currently under examination for income taxes by any other taxing ~~jurisdiction.~~jurisdictions. In the event of any future tax assessments, we have elected to record the income taxes and any related interest and penalties as income tax expense on our statement of operations.

~~Table of Contents~~

Note 9.11. Net Income ~~(Loss)~~ Per Share ~~Attributable to Common Stockholders~~

~~We adopted ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” in the fourth quarter of 2016 on a retrospective basis, effective January 1, 2016.~~ The following table sets forth the computation of our basic and diluted net income ~~(loss)~~ per ~~share attributable to common stockholders and reflects the adoption of ASU 2016-09:~~share:

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands, except share and per share data)

2017

2016

2017

2016

Net income

$
1,342

$
492

$
3,625

$
500

Convertible preferred stock dividends

—

224

—

1,247

Allocation of undistributed earnings to preferred stockholders

—

99

—

—

Net income (loss) attributable to common stockholders

$
1,342

$
169

$
3,625

$
(747)

Weighted-average shares outstanding

17,603,293

12,253,877

17,222,072

6,317,875

Effect of convertible preferred stock outstanding, restricted stock units, common stock options, warrants, and employee stock purchase plan shares

1,480,682

1,728,922

1,596,537

—

Weighted-average shares used to compute diluted net income (loss) per share

19,083,975

13,982,799

18,818,609

6,317,875

Net income (loss) per share - Basic

$
0.08

$
0.01

$
0.21

$
(0.12)

Net income (loss) per share - Diluted

$
0.07

$
0.01

$
0.19

$
(0.12)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
(In thousands, except share and per share data)	2018		2017		2018		2017
Net income	$	2,572	$	3,787	$	2,522	$	2,283
Weighted-average shares outstanding		18,155,543		17,176,386		18,076,546		17,028,237
Effect of restricted stock units, common stock options, warrants, and employee stock purchase plan shares		1,157,613		1,638,179		1,127,554		1,685,184
Weighted-average shares used to compute diluted net income per share		19,313,156		18,814,565		19,204,100		18,713,421
Net income per share - Basic	$	0.14	$	0.22	$	0.14	$	0.13
Net income per share - Diluted	$	0.13	$	0.20	$	0.13	$	0.12

The following common stock equivalents were excluded from the computation of diluted net income per share for the periods presented because including them would have been anti-dilutive:


	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended		Six Months Ended
	2017	2016	2017	2016	June 30,		June 30,
Convertible preferred stock outstanding	—	5,924,453	—	5,924,453
					2018	2017	2018	2017
Restricted stock units	—	—	1,184	—	8,238	—	8,238	66,517
Common stock options	23,311	—	63,066	1,628,754	110,521	39,755	120,521	111,500
Common stock warrants	—	—	—	5,800	—	—	—	1,122
Employee stock purchase plan					28,996	49,021	28,996	49,021
Total	23,311	5,924,453	64,250	7,559,007	147,755	88,776	157,755	228,160

~~As of September 30, 2017, total common shares outstanding and the potentially dilutive shares totaled approximately 19.2 million shares.~~

~~Table of Contents~~

Note ~~10.~~12. Fair Value Measurements

We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). The following provides information regarding fair value measurements for our cash equivalents and marketable securities as of ~~September~~June 30, ~~2017~~2018 and December 31, ~~2016~~2017 according to the three-level fair value ~~hierarchy.~~hierarchy:

Fair Value Measurements at

September 30, 2017 Using:


Quoted Prices






in Active

Significant

Markets for

Other

Significant

Identical

Observable

Unobservable

Assets

Inputs

Inputs

(In thousands)

(Level 1)

(Level 2)

(Level 3)

Total
Recurring Fair Value Measurements:

Money market mutual funds

$
8,110

$
—

$
—

$
8,110
U.S. government and agency obligations

2,003

10,965

—

12,968
Corporate debt securities

—

9,025

—

9,025
Total

$
10,113

$
19,990

$
—

$
30,103

Table of Contents


	As of June 30, 2018
	Quoted Prices
	in Active		Significant
	Markets for		Other		Significant
	Identical		Observable		Unobservable
	Assets		Inputs		Inputs
(In thousands)	(Level 1)		(Level 2)		(Level 3)		Total
Recurring Fair Value Measurements:
Money market mutual funds	$	11,614	$	—	$	—	$	11,614
U.S. government and agency obligations		8,864		8,958		—		17,822
Corporate debt securities		—		5,980		—		5,980
Total	$	20,478	$	14,938	$	—	$	35,416


	Fair Value Measurements at
	December 31, 2016 Using:								As of December 31, 2017
	Quoted Prices								Quoted Prices
	in Active		Significant						in Active		Significant
	Markets for		Other		Significant				Markets for		Other		Significant
	Identical		Observable		Unobservable				Identical		Observable		Unobservable
	Assets		Inputs		Inputs				Assets		Inputs		Inputs
(In thousands)	(Level 1)		(Level 2)		(Level 3)		Total		(Level 1)		(Level 2)		(Level 3)		Total
Recurring Fair Value Measurements:
Currency	$	14	$	—	$	—	$	14
Money market mutual funds		18,976		—		—		18,976	$	9,212	$	—	$	—	$	9,212
U.S. government and agency obligations		2,017		6,979		—		8,996		1,000		10,941		—		11,941
Corporate debt securities		—		1,998		—		1,998		—		8,003		—		8,003
Total	$	21,007	$	8,977	$	—	$	29,984	$	10,212	$	18,944	$	—	$	29,156

During the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, there were no transfers within the three-level hierarchy. A significant transfer is recognized when the inputs used to value a security have been changed, which merits a transfer between the disclosed levels of the valuation hierarchy.

The fair values for our ~~currency,~~ money market mutual funds, U.S. government and agency obligations and corporate debt securities are determined based on valuations provided by external investment managers who obtain them from a variety of industry standard data providers.

The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired. We had no re-measurements of non-financial assets to fair value in the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~

2018.

1718

Table of Contents

Note 13. Subsequent Event

On August 3, 2018, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association.

The Credit Agreement provides for a new $10,000,000 revolving credit facility. The revolving credit facility expires on August 3, 2021. Subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25,000,000 in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $35,000,000.

Amounts drawn under the revolving credit facility will bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) LIBOR for an interest period of one month plus 1% (the “Base Rate”) plus an applicable margin or (b) LIBOR plus the applicable margin. The applicable margin is 0.40% to 1.15% on loans bearing interest at the Base Rate and 1.40% to 2.15% on loans bearing interest at LIBOR, in each case depending on our consolidated total leverage ratio. Undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from 0.200% to 0.275%, depending on our consolidated total leverage ratio.

Our obligations under the Credit Agreement are secured by a security interest in substantially all of our assets and those of our subsidiaries and will also be guaranteed by our subsidiaries.

The Credit Agreement limits our ability to make capital expenditures during a fiscal year in excess of the amounts set forth in the Credit Agreement, and requires that we (i) not permit, as of the last day of each fiscal quarter, our consolidated total leverage ratio to exceed 3.00 to 1.00 and (ii) maintain minimum cash and cash equivalents, measured on the last day of each fiscal quarter, of not less than $7,500,000 (subject to a temporary reduction to $5,000,000 for the two fiscal quarters immediately following a permitted acquisition).

The Credit Agreement also contains certain other restrictions and covenants, which, among other things, restrict our ability to acquire or merge with another entity, dispose of our assets, make investments, loans or guarantees, incur additional indebtedness, create liens or other encumbrances, or pay dividends or make other distributions.

Amounts due under the Credit Agreement may be accelerated upon an Event of Default (as defined in the Credit Agreement), such as breach of a representation, covenant or agreement of ours, defaults with respect to certain of our other material indebtedness or the occurrence of bankruptcy if not otherwise waived or cured.

We may use the proceeds from advances under the revolving credit facility (i) to finance capital expenditures, (ii) to pay fees, commissions and expenses in connection with the Credit Agreement and (iii) for working capital and general corporate purposes.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the accompanying notes thereto included elsewhere in this report.

Overview

We are a medical technology company that develops and provides innovative medical devices for the treatment of chronic diseases. Our mission is to help people suffering from chronic diseases live better and care for themselves at home. We focus our efforts on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. Our initial area of therapeutic focus is vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency. We possess a unique, scalable platform to deliver at-home healthcare solutions throughout the United States. This evolving home care delivery model is recognized by ~~policy-makers~~policy makers and insurance payers as a key for controlling rising healthcare costs. Our solutions deliver cost-effective, clinically proven, long-term treatment for patients with these chronic diseases.

Our proprietary products are the Flexitouch, Entre, and Actitouch systems. A predecessor to our Flexitouch system received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) in July 2002, and we introduced the system to address the many limitations of self-administered home-based manual lymphatic drainage therapy. We began selling our more advanced Flexitouch system after receiving 510(k) clearance from the FDA in October 2006. In September 2016, we received 510(k) clearance from the FDA for the Flexitouch system in treating lymphedema of the head and neck. In June 2017, we announced that we received 510(k) clearance from the FDA for the Flexitouch Plus, the third-generation version of our Flexitouch system. We derive the vast majority of our revenues from our Flexitouch system. For the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, sales of our Flexitouch system represented ~~91%~~92% and ~~86%~~91% of our revenues, respectively.

In September 2012, we acquired our second proprietary product, the Actitouch system. The system received 510(k) clearance from the FDA in June 2013, and we began selling the product in September 2013 to address the many limitations of multilayered bandages that are worn by patients suffering from venous leg ulcers. We also introduced our Entre system in the United States in February 2013. The Entre system is sold to patients who need a more basic pump or who do not yet qualify for insurance reimbursement for an advanced compression device such as our Flexitouch system. For the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, sales of our Entre and Actitouch systems combined represented 9%8% and ~~14%~~9% of our revenues, respectively.

To support the growth of our business, we invest heavily in our commercial infrastructure, consisting of our direct ~~sales force,~~salesforce, home training resources, reimbursement capabilities and clinical expertise. We market our products in the United States using a direct-to-patient and -provider model. Our direct ~~sales force~~salesforce has grown from three representatives in March 2005 to a team of over ~~150~~170 people as of ~~September~~June 30, ~~2017.~~2018. This model allows us to directly approach patients and clinicians, whereby we disintermediate the traditional durable medical equipment channel, allowing us to capture both the manufacturer and distributor margins. We also utilize over ~~400~~500 licensed, independent healthcare practitioners as home trainers who educate patients on the proper use of our systems. We invest substantial resources in our reimbursement operations group of over 80 people that focuses on verifying case-by-case benefits, obtaining prior authorization, billing and collecting payments from payers, and providing customer support services. Our payer relations group of 3435 people is responsible for developing relationships with insurance payer decision-makers to educate them on our product efficacy, ~~develop~~developing overall payer coverage policies and reimbursement criteria, ~~manage~~managing Medicare patient claims and contracts with payers, and ~~serve~~serving as an advocacy liaison between patients, clinicians and payers throughout the appeals process. We also have a clinical team, consisting of a scientific advisory board, ~~as well as~~ in-house therapists and nurses,and a medical director (part-time), that serves as a resource to clinicians and patients and guides the development of clinical evidence in support of our products.

Our patients are reimbursed by government and private payers for the purchase of our products pursuant to established rates with each payer. We rely on third-party contract manufacturers for the sourcing of parts, the assembly of our controllers and the manufacturing of the garments used with our systems. We conduct final assembly of the garments used with our Flexitouch system, perform quality assurance, and ship our products from our facility in Minneapolis, Minnesota.

1820

Table of Contents

For the three months ended ~~September~~June 30, ~~2017,~~2018, we generated revenues of ~~$28.3~~$34.1 million and had net income of ~~$1.3~~$2.6 million, compared to revenues of ~~$22.6~~$26.3 million and net income of ~~$0.5~~$3.8 million for the three months ended ~~September~~June 30, ~~2016.~~2017. For the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, we generated revenues of ~~$74.4~~$61.0 million and had net income of ~~$3.6~~$2.5 million, compared to revenues of ~~$56.1~~$46.1 million and net income of ~~$0.5~~$2.3 million for the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~217. Our primary sources of capital to date have been from operating income, private placements of our capital stock, and capital raised in our initial public offering, which closed on August 2, 2016. We operate in one segment for financial reporting purposes.

Results of Operations

Comparison of the Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017

The following tables present our results of operations for the periods indicated.


	Three Months Ended September 30,								Change				Three Months Ended
(In thousands, except percentages)	2017				2016				$		%
Condensed Consolidated Statement of Operations Data:			% of revenue				% of revenue
													June 30,								Change
(Dollars in thousands)													2018				2017				$		%
Condensed Consolidated Statement of															% of				% of
Operations Data:															revenue				revenue
Revenues	$	28,283	100	%	$	22,635	100	%	$	5,648	25	%	$	34,133	100	%	$	26,264	100	%	$	7,869	30	%
Cost of goods sold		7,528	27			6,282	28			1,246	20			9,610	28	%		7,034	27	%		2,576	37	%
Gross profit		20,755	73			16,353	72			4,402	27			24,523	72	%		19,230	73	%		5,293	28	%
Operating expenses
Sales and marketing		10,915	38			8,979	40			1,936	22			14,452	42	%		10,645	41	%		3,807	36	%
Research and development		1,116	4			1,285	6			(169)	(13)			1,289	4	%		1,465	6	%		(176)	(12)	%
Reimbursement, general and administrative		7,551	26			5,115	22			2,436	48			7,471	22	%		6,390	23	%		1,081	17	%
Total operating expenses		19,582	68			15,379	68			4,203	27			23,212	68	%		18,500	70	%		4,712	25	%
Income from operations		1,173	5			974	4			199	20			1,311	4	%		730	3	%		581	80	%
Other income		85	—			10	—			75	750			132	—	%		64	—	%		68	106	%
Income before income taxes		1,258	5			984	4			274	28			1,443	4	%		794	3	%		649	82	%
Income tax (benefit) expense		(84)	—			492	2			(576)	(117)
Income tax benefit														(1,129)	(4)	%		(2,993)	(11)	%		1,864	(62)	%
Net income	$	1,342	5		$	492	2		$	850	173		$	2,572	8	%	$	3,787	14	%	$	(1,215)	(32)	%


	Nine Months Ended September 30,								Change				Six Months Ended
(In thousands, except percentages)	2017				2016				$		%
Condensed Consolidated Statement of Operations Data:			% of revenue				% of revenue
													June 30,								Change
(Dollars in thousands)													2018				2017				$		%
Condensed Consolidated Statement of															% of				% of
Operations Data:															revenue				revenue
Revenues	$	74,397	100	%	$	56,064	100	%	$	18,333	33	%	$	60,981	100	%	$	46,114	100	%	$	14,867	32	%
Cost of goods sold		20,186	27			15,417	27			4,769	31			16,919	28	%		12,658	27	%		4,261	34	%
Gross profit		54,211	73			40,647	73			13,564	33			44,062	72	%		33,456	73	%		10,606	32	%
Operating expenses
Sales and marketing		31,726	42			23,858	43			7,868	33			27,009	45	%		20,811	45	%		6,198	30	%
Research and development		3,699	5			3,314	6			385	12			2,726	4	%		2,583	6	%		143	6	%
Reimbursement, general and administrative		19,815	27			12,495	22			7,320	59			14,843	24	%		12,264	27	%		2,579	21	%
Total operating expenses		55,240	74			39,667	71			15,573	39			44,578	73	%		35,658	78	%		8,920	25	%
(Loss) income from operations		(1,029)	(1)			980	2			(2,009)	(205)
Loss from operations														(516)	(1)	%		(2,202)	(5)	%		1,686	(77)	%
Other income		204	—			20	—			184	920			223	—	%		119	—	%		104	87	%
(Loss) income before income taxes		(825)	(1)			1,000	2			(1,825)	(183)
Income tax (benefit) expense		(4,450)	(6)			500	1			(4,950)	(990)
Loss before income taxes														(293)	(1)	%		(2,083)	(5)	%		1,790	(86)	%
Income tax benefit														(2,815)	(5)	%		(4,366)	(10)	%		1,551	(36)	%
Net income	$	3,625	5		$	500	1		$	3,125	625		$	2,522	4	%	$	2,283	5	%	$	239	10	%

1921

Table of Contents

Revenues

Revenues increased ~~$5.7~~$7.9 million, or ~~25%~~30%, to ~~$28.3~~$34.1 million in the three months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$22.6~~$26.3 million in the three months ended ~~September~~June 30, ~~2016.~~2017. Revenues increased ~~$18.3~~$14.9 million, or ~~33%~~32%, to ~~$74.4~~$61.0 million in the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$56.1~~$46.1 million in the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2017. The growth in revenues was attributable to an increase of approximately ~~$6.8~~$7.1 million, or ~~35%~~30%, in sales of our Flexitouch system ~~for~~in the three months ended ~~September~~June 30, ~~2017~~2018 and an increase of approximately ~~$19.9~~$14.2 million, or ~~42%~~34%, in sales of our Flexitouch system ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017. These increases~~2018. The increase in Flexitouch system sales ~~were~~was largely driven by expansion of our ~~sales force and~~salesforce, growth in the Veterans Administration channel, increased physician and patient awareness of the treatment options for lymphedema, ~~as well as increased~~and expanded contractual coverage with national and regional insurance payers. The increases in sales of our Flexitouch system were partially offset by decreases of 36% and 20% in sales of our Entre and Actitouch systems in the three and nine months ended September 30, 2017 compared to the same periods in 2016, respectively.

Revenues from the Veterans Administration ~~hospitals~~ represented 20% and ~~13%~~18% of total revenues ~~for~~in the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively. Revenues from the Veterans Administration ~~hospitals~~ represented ~~19%~~21% and ~~16%~~18% of total revenues ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively. Revenues from Medicare represented 6%4% and ~~13%~~9% of total revenues ~~for~~in the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively. Revenues from Medicare represented 9%5% and ~~13%~~10% of total revenues ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively.

The following tables summarize our revenues by product for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, both in dollars and percentage of total revenues:


	Three Months Ended September 30,						Change		Three Months Ended
(In thousands, except percentages)	2017			2016			%
									June 30,				Change
(Dollars in thousands)									2018		2017		$		%
Revenues
Flexitouch system	$	26,202		$	19,387		35	%	$	31,356	$	24,208	$	7,148	30 %
Entre/Actitouch systems		2,081			3,248		(36)	%		2,777		2,056		721	35 %
Total	$	28,283		$	22,635		25	%	$	34,133	$	26,264	$	7,869	30 %

Percentage of total revenues
Flexitouch system		93	%		86	%				92 %		92 %
Entre/Actitouch systems		7	%		14	%				8 %		8 %
Total		100	%		100	%				100 %		100 %


	Nine Months Ended September 30,						Change		Six Months Ended
(In thousands, except percentages)	2017			2016			%
									June 30,				Change
(Dollars in thousands)									2018		2017		$		%
Revenues
Flexitouch system	$	67,936		$	47,988		42	%	$	55,886	$	41,734	$	14,152	34 %
Entre/Actitouch systems		6,461			8,076		(20)	%		5,095		4,380		715	16 %
Total	$	74,397		$	56,064		33	%	$	60,981	$	46,114	$	14,867	32 %

Percentage of total revenues
Flexitouch system		91	%		86	%				92 %		91 %
Entre/Actitouch systems		9	%		14	%				8 %		9 %
Total		100	%		100	%				100 %		100 %

2022

Table of Contents

Medicaid, or the Veterans Administration, ~~hospitals,~~ as those payers either do not have plans that have declining deductibles over the course of the plan year or do not have plans that include patient deductibles for purchases of our products.

Cost of Goods Sold and Gross Margin

Cost of goods sold increased ~~$1.2~~$2.6 million, or ~~20%~~37%, to ~~$7.5~~$9.6 million ~~for~~in the three months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$6.3~~$7.0 million ~~for~~in the three months ended ~~September~~June 30, ~~2016.~~2017. Cost of goods sold increased ~~$4.8~~$4.3 million, or ~~31%~~34%, to ~~$20.2~~$16.9 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$15.4~~$12.7 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2017. The increase in cost of goods sold ~~for~~in the each of the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 compared to the same periods in ~~2016~~2017 was primarily attributable to an increase in the number of Flexitouch systems sold, ~~and~~as well as additional manufacturing headcount to support increased volumes.

Gross margin was ~~73% and~~ 72% of sales ~~for~~in each of the three and six months ended ~~September~~June 30, ~~2017 and 2016, respectively.~~2018. Gross margin was 73% of sales ~~for both~~in each of the ~~nine~~three and six months ended ~~September~~June 30, ~~2017 and 2016.~~2017.

Sales and Marketing Expenses

Sales and marketing expenses increased ~~$1.9~~$3.8 million, or ~~22%~~36%, to ~~$10.9~~$14.5 million ~~for~~in the three months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$9.0~~$10.6 million ~~for~~in the three months ended ~~September~~June 30, ~~2016. This~~2017. The year-over-year increase was ~~largely~~primarily driven by a ~~$0.6 million increase in variable sales compensation, a $0.5~~$2.8 million increase in personnel-related compensation ~~expenses~~expense due to increased sales and marketing headcount, ~~and $0.2~~including $0.4 million of incremental stock-based compensation expense. In addition, other sales and marketing expenses increased ~~$0.6~~$1.0 million, ~~due to~~driven by increased spending associated with field sales meetings, travel and entertainment, consulting ~~recruitment~~ and field sales training expenses, ~~as well as increased patient~~including training ~~costs.~~associated with the full commercial launch of the Flexitouch Plus that began in April 2018.

Sales and marketing expenses increased ~~$7.8~~$6.2 million, or ~~33%~~30%, to ~~$31.7~~$27.0 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$23.9~~$20.8 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2017. The year-over-year increase was primarily driven by a ~~$2.0~~$4.3 million increase in personnel-related compensation ~~expenses~~expense due to increased sales and marketing headcount, ~~a $1.9~~including $0.8 million ~~increase in variable sales compensation and $0.8 million~~of incremental stock-based compensation expense. In addition, other sales and marketing expenses increased ~~$3.1~~$1.9 million, ~~due to~~driven by increased spending associated with field sales meetings, travel and entertainment, consulting ~~recruitment,~~ and field sales training expenses, ~~as well as increased patient~~including training ~~costs.~~associated with the full commercial launch of the Flexitouch Plus that began in April 2018.

Research and Development Expenses

Research and development (“R&D”) expenses decreased $0.2 million, or ~~13%~~12%, to ~~$1.1~~$1.3 million ~~for~~in the three months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$1.3~~$1.5 million ~~for~~in the three months ended ~~September~~June 30, ~~2016.~~2017. The year-over-year decrease was primarily ~~related~~attributable to ~~a decline in personnel-related~~decreased clinical studies expenses.

R&D expenses increased ~~$0.4~~$0.1 million, or ~~12%~~6%, to ~~$3.7~~$2.7 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$3.3~~$2.6 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2017. The year-over-year increase ~~in R&D~~was primarily attributable to increased engineering consulting expenses, ~~was due to a $0.2 million increase in personnel-related expenses and a $0.2 million increase in product development and consulting expense.~~partially offset by decreased clinical studies expenses.

Reimbursement, General and Administrative Expenses

Reimbursement, general and administrative expenses increased ~~$2.5~~$1.1 million, or ~~48%~~17%, to ~~$7.6~~$7.5 million ~~for~~in the three months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$5.1~~$6.4 million ~~for~~in the three months ended ~~September~~June 30, ~~2016.~~2017. This increase was primarily attributable to an increase of $0.9 million in professional fees including legal, accounting and audit expenses, including approximately $0.5 million of expenses associated with the secondary offering of shares of our common stock by certain selling stockholders in September 2017, which expenses we paid on behalf of the selling stockholders pursuant to an investors’ rights agreement. Additionally, the increase in reimbursement, general and administrative expenses included an increase of $0.8 million related to accrued sales and use and franchise taxes, a ~~$0.4~~$0.7 million increase in personnel-related ~~expenses resulting from~~compensation expense as a result of increased headcount in our reimbursement operations, payer relations and corporate functions, ~~and~~including $0.1 million of incremental stock-based compensation expense, as well as a ~~$0.1~~$0.3 million increase in ~~stock-based compensation expense.~~professional fees, legal expenses and volume-based service charges.

Reimbursement, general and administrative expenses increased ~~$7.3~~$2.6 million, or ~~59%~~21%, to ~~$19.8~~$14.8 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, compared to ~~$12.5~~$12.3 million ~~for~~in the ~~nine~~six months ended ~~September~~June 30, ~~2016. The~~2017. This increase was primarily attributable to a $1.6 million increase in personnel-related compensation expense as a result of increased headcount in our reimbursement operations, payer relations and corporate functions, including $0.3 million of incremental stock-based

2123

Table of Contents

~~increase in reimbursement, general and administrative expenses for the nine months ended September 30, 2017 was primarily attributable to~~compensation expense, as well as a ~~$2.0~~$0.9 million increase in ~~personnel-related expenses resulting from increased headcount in our reimbursement operations, payer relations, and corporate functions, an increase of $1.9 million in~~ professional fees, ~~including~~ legal ~~accounting~~expenses and audit expenses associated with public company requirements and $0.5 million of expenses associated with the September 2017 secondary offering, a $1.4 million increase in stock-based compensation expense and an increase of $1.0 million related to accrued sales and use and franchise taxes.volume-based service charges.

Other Income, Net

Other income was ~~$85,000~~$132,000 and ~~$10,000~~$64,000 for the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~,2017, respectively, and ~~$0.2 million~~$223,000 and ~~$20,000~~$119,000 for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, respectively. The increase in other income ~~in both periods~~ was primarily due to investment income earned on our ~~invested capital derived from our initial public offering proceeds.~~marketable securities.

Income Taxes

We recorded an income tax benefit of ~~$0.1~~$1.1 million and ~~income tax expense of $0.5~~$3.0 million ~~for~~in the three months ended ~~September~~June 30, 2018 and 2017, respectively. An income tax benefit of $2.8 million and ~~2016,~~$4.4 million was recorded in the six months ended June 30, 2018 and 2017, respectively. The ~~current period~~continued significant tax ~~benefit was primarily due~~deductions related to ~~a significant increase in~~ tax benefits ~~related to tax-deductible share-based compensation activity recognized in the current quarter as compared to the previous reporting period. Significant tax deductions resulted~~realized from ~~windfall benefits with respect to~~ the vesting of restricted stock units, ~~excess tax benefits associated with exercises~~the exercise of non-qualified stock options, and the disqualifying dispositions of incentive stock options and ESPP ~~shares. These~~shares contributed to our net income ~~tax benefits in the current reporting period resulted in a significant increase in our earnings per share~~ for the ~~period.~~

~~We recorded an income tax benefit of $4.5 million~~three and ~~income tax expense of $0.5 million for the nine~~six months ended ~~September~~June 30, 2017 and 2016, respectively. The current period tax benefit was primarily due to a significant increase in tax benefits related to tax-deductible share-based compensation activity as compared to the previous reporting period. This activity included vesting of restricted stock awards and restricted stock units, excess tax benefits associated with exercises of non-qualified stock options, and disqualifying dispositions of incentive stock options and ESPP shares. These income tax benefits in the current year resulted in a significant increase in our earnings per share for the nine months ended September 30, 2017.2018.

Liquidity and Capital Resources

Cash Flows

At ~~September~~June 30, ~~2017,~~2018, our principal sources of liquidity were cash and cash equivalents of ~~$19.7~~$17.3 million, marketable securities of ~~$22.0~~$23.8 million and net accounts receivable of ~~$14.6~~$17.5 million.

The following table summarizes our cash flows for the periods indicated:


	Nine Months Ended				Six Months Ended
	September 30,				June 30,
(In thousands)	2017		2016		2018		2017
Net cash provided by (used in):
Net cash (used in) provided by:
Operating activities	$	33	$	4,336	$	(1,399)	$	(3,015)
Investing activities		(13,193)		(542)		(5,445)		(11,733)
Financing activities		2,112		28,440		196		2,143
Net (decrease) increase in cash and cash equivalents	$	(11,048)	$	32,234
Net decrease in cash and cash equivalents					$	(6,648)	$	(12,605)

~~Net Cash Provided by~~

Operating Activities

Net cash ~~provided by~~used in operating activities during the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 was ~~$33,000. This source of cash was primarily~~$1.4 million, resulting from net income of ~~$3.6~~$2.5 million and non-cash net income adjustments of ~~$4.1~~$5.2 million, ~~including $3.1~~which were more than offset by a net increase in operating assets and liabilities of $9.1 million. The non-cash net income adjustments primarily consisted of $3.3 million of stock-based compensation expense and ~~$1.1~~$1.7 million of depreciation and amortization expense. The changes in net operating assets and liabilities were primarily due to a $5.4 million increase in inventories, associated with the commercial launch of our Flexitouch Plus system, and a $3.1 million increase in income taxes receivable, driven by the current period tax benefit associated with tax-deductible stock-based compensation activity.

Net cash used in operating activities during the six months ended June 30, 2017 was $3.0 million. This ~~source~~use of cash was ~~partially offset by~~primarily due to a ~~$7.7~~$7.8 million increase in net operating assets and liabilities, ~~primarily related to~~driven by increases in income taxes receivable and payroll-related accruals and an increase in inventories, partially offset by net income of ~~$5.6~~$2.3 million and ~~inventory~~non-cash net income adjustments of ~~$3.8 million. The increase~~$2.5 million, including $2.1 million of stock-based compensation expense.

Investing Activities

Net cash used in ~~income taxes~~investing activities during the six months ended June 30, 2018 was $5.4 million, consisting primarily of $2.8 million in net purchases of marketable securities, $0.9 million in purchases of rental and demonstration equipment, $0.9 million related to the acquisition of patents and other intangible assets and $0.8 million in purchases of product tooling and computer and manufacturing equipment.

2224

Table of Contents

receivable was a result of the significant tax benefits recognized in the period associated with tax-deductible share-baesd compensation activity. The increase in inventory was driven largely by the increased sales volume as well as purchases associated with product development and new product introductions.

Net cash provided by operating activities during the nine months ended September 30, 2016 was $4.3 million. This source of cash primarily resulted from net income of $0.5 million, a $1.8 million decrease in net operating assets and liabilities, including a $1.7 million increase in accounts payable on increased inventory purchases and other operating expenses, and $2.0 million of non-cash expense items, including $0.9 million of stock-based compensation expense and $0.7 million of depreciation and amortization expense.

~~Net Cash Used in Investing Activities~~

Net cash used in investing activities during the ~~nine~~six months ended ~~September~~June 30, 2017 was ~~$13.2~~$11.7 million, consisting primarily of ~~$11.1~~$10.0 million in net purchases of marketable securities and ~~$2.0~~$1.5 million in purchases of product tooling ~~computer~~ and ~~manufacturing equipment, and leasehold improvements.~~

~~Net cash used in investing activities during the nine months ended September 30, 2016 was $0.5 million, consisting primarily of purchases of product tooling,~~ computer and manufacturing equipment.

~~Net Cash Provided by~~ Financing Activities

Net cash provided by financing activities during the ~~nine~~six months ended ~~September~~June 30, 2018 was $0.2 million, consisting of proceeds from the issuance of common stock under the ESPP of $1.4 million and proceeds from exercises of common stock options of $0.6 million, partially offset by $1.8 million in taxes paid for the net share settlement of stock-settled restricted stock units.

Net cash provided by financing activities during the six months ended June 30, 2017 was $2.1 million, consisting of proceeds from the issuance of common stock under the ESPP of $2.2 million and proceeds from exercises of common stock options and warrants of ~~$0.7~~$0.6 million, partially offset by the purchase of treasury stock to ~~fund~~cover taxes ~~from~~associated with restricted stock award vesting of $0.5 million and taxes paid for the net share settlement of stock-settled restricted stock units of ~~$0.3~~$0.2 million.

Net cash provided by financing activities during the nine months ended September 30, 2016 was $28.4 million, generated by gross proceeds of $41.2 million from our initial public offering, partially offset by $8.2 million in payments of accrued dividends on preferred stock and $4.8 million of underwriting discounts and expenses associated with the initial public offering.

~~Credit Line~~

~~At December 31, 2016 we had a $2.0 million line of credit with a bank that bore interest based on the prime rate. There was no outstanding balance on the line of credit as of December 31, 2016.The line of credit expired on May 11, 2017, and there was no outstanding balance on the line as of that date.~~

Adequacy of Capital Resources

Our future capital requirements may vary significantly from those now planned and will depend on many factors, including:

sales and marketing resources needed to further penetrate our market;

expansion of our operations domestically and/or internationally;

~~response~~responses of competitors to our solutions and applications;

costs associated with clinical research activities;

costs to develop and implement new products; and

use of capital for acquisitions, if any.

~~Table of Contents~~

Historically, we have experienced increases in our expenditures consistent with the growth in our revenues, operations and personnel, and we anticipate that our expenditures will continue to increase as we expand our business.

We believe our cash, cash equivalents, marketable securities, ~~and any~~ cash flows from operations and our credit facility will be sufficient to meet our working capital and capital expenditure requirements for at least the next twelve months. ~~We expect continued increased expenses in connection with meeting our obligations as a public company.~~

Inflation and changing prices did not have a material effect on our business during the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, and we do not expect that inflation or changing prices will materially affect our business in the foreseeable future.

On August 3, 2018, we entered into the Credit Agreement. Our obligations under the Credit Agreement are secured by a security interest in substantially all of our assets and those of our subsidiaries and will also be guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio and a minimum liquidity covenant. For additional information on the Credit Agreement, see Note 13 – “Subsequent Event” to the condensed consolidated financial statements in this report.

In August 2017, we filed a shelf registration statement on Form S-3 with the SEC. Under the shelf registration statement, we may offer and sell from time to time up to $200 million of common stock, preferred stock, debt securities, warrants, rights or units. The shelf registration statement also registered for resale from time to time up to 5,703,534 shares of our common stock held by the selling stockholders named therein. In September 2017, certain of the selling stockholders completed a secondary offering of 3,795,000 shares of our common stock at a public offering price of $33.00 per share. We did not receive any proceeds from the sale of the shares by the selling stockholders.

Table of Contents

Contractual and Commercial Commitments Summary

Our contractual obligations and commercial commitments as of ~~September~~June 30, ~~2017~~2018 are summarized below:


	Payments Due By Period										Payments Due By Period
			Less Than						More Than				Less Than						More Than
(In thousands)	Total		1 Year		1-3 Years		3-5 Years		5 Years		Total		1 Year		1-3 Years		3-5 Years		5 Years
Operating lease obligations (1)	$	3,084	$	807	$	1,557	$	720	$	—
Purchase commitments (2)		15,719		15,719		—		—		—
Purchase commitments (1)											$	5,917	$	5,917	$	—	$	—	$	—
Operating lease obligations (2)												2,969		993		1,679		297		—
Future product royalties (3)												9		9		—		—		—
Total	$	18,803	$	16,526	$	1,557	$	720	$	—	$	8,895	$	6,919	$	1,679	$	297	$	—

(1)

We issued purchase orders in 2017 totaling $5.9 million for items that we expect to receive between July and December of 2018.

~~(1)~~(2)

We currently lease approximately 52,000 square feet of office space at our corporate headquarters in Minneapolis, Minnesota under a lease that expires in July 2021 and an additional ~~31,200~~38,520 square feet of office, assembly and warehouse space at a second leased facility in Minneapolis, Minnesota under a lease that expires in November 2021. We ~~also~~ entered into a fleet vehicle ~~lease~~ program for certain members of our field sales organization in 2016. At ~~September~~June 30, ~~2017,~~2018, we had 2617 vehicles ~~with future lease obligations~~ under this ~~program.~~program with current lease commitments.

~~(2)~~(3)

~~Represents purchase orders issued~~We are required to make quarterly royalty payments to a third party for our Actitouch system revenues through August 2023. Beginning in ~~January through October~~September 2017, the payments are equal to ~~vendors for inventory expected~~6% of our quarterly revenues attributable to our Actitouch system. In any year that these revenues exceed $40.0 million, we are required to pay 7% on revenues over $40.0 million and 6% on revenues of $40.0 million and under. Because our revenues attributable to our Actitouch system, and therefore the amount of royalty payments we will be ~~received~~required to pay in the ~~remainder~~future, are unknown, this amount only reflects royalties due associated with a portion of ~~2017 through September 2018.~~our 2018 Actitouch revenues.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, investments in special purpose entities or undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic leases.

Recent Accounting Pronouncements

Refer to Note 13 - ~~“Nature~~“Summary of ~~Operations and Basis of Presentation”~~Significant Accounting Policies” of our condensed consolidated financial statements contained in this report for a description of recently issued accounting pronouncements that are applicable to our business.

JOBS Act

We currently are an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We ~~have~~ elected to avail ourselves of this exemption and, as a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable.

~~Table~~ However, as of ~~Contents~~

the last business day of our second fiscal quarter of 2018, the market value of our common stock that was held by non-affiliates exceeded $700 million, and as a result, we will no longer qualify as an emerging growth company as of December 31, 2018 and will no longer be able to take advantage of the extended transition period.

Subject to certain conditions, as an emerging growth company, we currently are relying on certain of the exemptions and reduced reporting requirements of the JOBS Act, including without limitation, from providing an auditor's attestation report on our system of internal ~~controls~~control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 and from complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. ~~We will remain an emerging growth company until~~Because the ~~earliest of: (a)~~market value of our common stock that was held by non-affiliates as of the last business day of ~~the~~our second fiscal ~~year in which~~quarter of 2018 exceeded $700 million, we have total annual gross revenues of $1.07 billion or more; (b) the last day of 2021; (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (d) the date on which we arewill be deemed ~~to be~~ a large accelerated filer ~~under the rules~~as of December 31, 2018 and will no longer qualify as an emerging growth company. As a result, we will no longer be able to take advantage of the ~~SEC.~~reduced disclosure and other benefits available to emerging growth companies after that date, including our exemption from providing our auditor’s

Table of Contents

attestation on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002. See Part II, Item 1A., “Risk Factors” of this Quarterly Report on Form 10-Q for further discussion of these matters.

Critical Accounting Policies and Estimates

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results and requires management’s most subjective or complex judgments, often as a result of the need to make estimates about the effect of items that are inherently uncertain. For additional information, please see the discussion of our significant accounting policies under “Critical Accounting Policies and Significant Estimates” in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

We are exposed to market risk from changes in interest rates, primarily related to our investment activities. The principal objectives of our investment activities are to preserve principal, provide liquidity and maximize income consistent with minimizing risk of material loss. The recorded carrying amounts of cash and cash equivalents approximate fair value due to their short maturities. Our interest income is sensitive to changes in the general level of interest rates in the United States, particularly since our investments are generally short-term in nature. Based on the nature of our short-term investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

Inflation

Inflationary factors, such as increases in our cost of goods sold, sales and marketing expenses and reimbursement expenses, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial condition or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin, and on our sales and marketing and reimbursement expenses as a percentage of our revenues, if the selling prices of our products do not increase as much or more than these increased costs.

Credit Risk

As of ~~September~~June 30, ~~2017~~2018 and December 31, ~~2016,~~2017, our cash, cash equivalents and marketable securities were maintained with two financial institutions in the United States. We have reviewed the financial statements of these institutions and believe they have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us.

Our accounts receivable primarily relate to revenues from the sale of our products to patients in the United States. As of ~~September 30,~~June, 2018 and 2017, ~~and 2016,~~ our accounts receivable were ~~$17.4~~$19.2 million and ~~$14.7~~$15.9 million, respectively. We had accounts receivable from three insurance companies representing approximately ~~28%~~25%, ~~17%~~12% and 6%9% of accounts receivable as of ~~September~~June 30, ~~2017,~~2018, and we had accounts receivable from three insurance companies representing approximately ~~23%~~26%, ~~12%~~17% and 6%5% of accounts receivable as of ~~September~~June 30, ~~2016.~~2017.

2527

Table of Contents

Foreign Currency Risk

Our business is conducted in U.S. dollars and international transactions have been minimal. As we begin building relationships to commercialize and distribute our products internationally, our results of operations and cash flows may become increasingly subject to changes in foreign exchange rates.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of ~~September~~June 30, ~~2017.~~2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of ~~September~~June 30, ~~2017,~~2018, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were ~~effective.~~effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no material changes in our internal control over financial reporting during the three months ended ~~September~~June 30, ~~2017~~2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2628

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be subject to various claims and legal proceedings arising in the ordinary course of business. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Item 1A. Risk Factors.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017, which could materially affect our business, financial condition or future results. Except as set forth below, ~~there~~there have been no material changes in our risk factors from those disclosed in that report. The following risk factors are revised or added:

~~Healthcare reform measures could hinder or prevent the commercial success of~~Increases in our ~~products and product candidates.~~

In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future revenues and profitability and the future revenues and profitability of our customers. Federal and state lawmakers regularly propose and, at times, enact legislation that results in significant changes to the healthcare system, some of which are intended to contain or reduce theoperating costs of medical products and services. The new presidential administration and U.S. Congress have sought, and we expect that they will continue to seek, to modify, repeal, or otherwise invalidate all, or certain provisions of, the Patient Protection and Affordable Care Act and Health Care Education Reconciliation Act (the “Affordable Care Act”). There is still uncertainty with respect to the impact that the current administration and legislative action may have, if any, and any changes will likely take time to unfold and could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the Affordable Care Act. Such uncertainty and any changes could negatively impact our ability to successfully commercialize our products or product candidates, and could result in reduced demand for our products and additional pricing pressures.

~~We may be adversely affected by natural disasters and other catastrophic events, and by man-made problems such as terrorism, that could disrupt our business operations.~~

Natural disasters or other catastrophic events may cause damage or disruption to our operations, including causing delays in completing sales, continuing production or performing other critical functions of our business, which could have an adverse effect on our ~~business,~~financial condition and results of operations.

Reimbursement rates are established by fee schedules mandated by private payers, Medicare, the Veterans Administration and certain Medicaid programs and are likely to remain constant or decrease due, in part, to federal and state government budgetary constraints. As a result, with respect to Medicare and Medicaid related revenues, we may not be able to offset the effects of general inflation on our operating ~~results~~costs through increases in prices for our products. In particular, labor and financial condition. Our business operations are subject to interruption by natural disasters, fire, power shortages, pandemics, and other events beyond our control. In addition, acts of terrorism and other geo-political unrest could cause disruptions in our business or the businessesrelated costs account for a significant portion of our ~~partners~~operating costs and we compete with other healthcare providers to attract and retain qualified or ~~the economy as a whole. In the event of a natural disaster, including a major earthquake, blizzard or hurricane, or a catastrophic event~~skilled personnel and with various industries for administrative and service employees. This competitive environment could result in increased labor costs. As such, ~~as a fire, power loss, or telecommunications failure,~~ we ~~may be unable~~must control our operating costs, particularly labor and related costs, and failing to continue our operations for a period of time in the affected area, which could have an adverse effect on our future operating results. For example, recent and impending hurricanes, such as Hurricane Harvey and Hurricane Irma, may disrupt orders for our products and our ability to fulfill orders for a period of time.

~~We may be subject to liabilities related to state income, sales and use taxes, which~~do so could adversely affect our financial ~~condition~~conditions and results of ~~operations and could decrease demand for our products.~~operations.

~~State income tax and sales and use tax laws, statutes, rules and regulations vary greatly by jurisdiction and are complex and subject to uncertainty. We are~~Our operating costs may fluctuate significantly in the ~~process~~future as a result of ~~reviewing the various requirements related to these types~~a variety of ~~taxes, but at this time we cannot predict the outcome~~factors, many of that review. If it is determined that certain of these tax rules apply to us, we could be required to pay substantial tax amounts, and significant penalties and interest for past amounts that may have been due, in addition to taxes going forward. These tax assessments, penalties and interest, and future requirements, may adversely affect our financial condition and results of operations. In addition, the imposition of sales and use taxes on our products going forward would effectively increase the costwhich are outside of our ~~products to our customers and may adversely affect demand for our products.~~control. These factors include:


			increased sales and marketing costs to increase awareness of our products;
			costs to develop new and enhanced features for current products and research and development costs for new products;
			the time, resources, and expense required to develop and conduct clinical trials and seek additional regulatory clearances and approvals for additional treatment indications for our products and for any additional products we develop;
			the costs of preparing, filing, prosecuting, defending, and enforcing patent claims and other patent related costs, including litigation costs and the results of such litigation;
			any product liability or other lawsuits related to our products and the costs associated with defending them or the costs related to the results of such lawsuits;
			the costs to attract and retain personnel with the skills required for effective operations;
			the costs associated with being a public company, which will increase further once we no longer qualify as an emerging growth company as of December 31, 2018; and
			costs associated with entering international markets.

2729

Table of Contents

Our failure to anticipate and minimize the impact of these costs could adversely affect our business and results of operations.

We may be unable to manage our growth effectively.

Our past growth has provided, and our future growth may create, challenges to our organization. For instance, from March 2005 to June 30, 2018, the number of our employees increased from 10 to 426. We intend to continue to grow and may experience periods of rapid growth and expansion. Future growth will impose significant added responsibilities on management, including the need to identify, recruit, train, integrate, retain and motivate additional employees. In addition, rapid and significant growth will place a strain on our administrative personnel, information technology systems and other operational infrastructure. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.

Successful growth is also dependent upon our ability to implement appropriate financial and management controls, systems and procedures. In order to manage our operations and growth, we will need to continue to improve our operational and management controls, reporting and information technology systems and financial internal control procedures, which will become more complex once we no longer qualify as an emerging growth company as of December 31, 2018. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and there could be an adverse impact on our business.

We currently are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.

We currently are an emerging growth company, as defined in the JOBS Act, but, based on the market value of our common stock held by non-affiliates as of the last business day of our second fiscal quarter of 2018, we will no longer qualify as an emerging growth company as of December 31, 2018. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We have taken advantage of reduced reporting burdens in previous reports and filings, as well as in this report. We cannot predict whether investors will find our common stock less attractive while we continue to rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, as a result, our financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. We cannot predict whether investors will find our common stock less attractive while we continue to rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.

As of December 31, 2018, we will no longer be an emerging growth company and, as a result, we will have to comply with increased disclosure and compliance requirements.

As a result of the market value of our common stock held by non-affiliates exceeding $700 million as of the last business day of our second fiscal quarter of 2018, we will be deemed a large accelerated filer and we will no longer qualify as an emerging growth company as of December 31, 2018. Accordingly, we will be subject to certain disclosure and compliance requirements that apply to other public companies but did not previously apply to us due to our status as an emerging growth company. These requirements include:


			the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002;
			that we adopt new or revised accounting standards when they are applicable to public companies, instead of delaying their adoption until they are applicable to private companies;

Table of Contents



compliance with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;



the requirement that we provide full and more detailed disclosures regarding executive compensation; and



the requirement that we hold a non-binding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved.

We expect that the loss of emerging growth company status and compliance with the additional requirements of being a large accelerated filer will increase our legal and financial compliance costs and cause management and other personnel to divert attention from operational and other business matters to devote substantial time to public company reporting requirements. In addition, if we are not able to comply with changing requirements in a timely manner, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC, or other regulatory authorities, which would require additional financial and management resources.

We are incurring increased costs and are subject to additional regulations and requirements as a result of being a public company, which costs and requirements will increase in connection with us no longer qualifying as an emerging growth company, which could lower our profits or make it more difficult to run our business.

As a public company, we have incurred, and are continuing to incur, significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements and costs associated with the Sarbanes-Oxley Act and related rules implemented by the SEC and Nasdaq. These expenses and costs will increase as we prepare for, and following, us no longer qualifying as an emerging growth company as of December 31, 2018. These expenses could lower our profits or make it more difficult to run our business.

Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation.

If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors' views of us and, as a result, the value of our common stock.

Pursuant to Section 404 of the Sarbanes-Oxley Act, our management was required to report upon the effectiveness of our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ended December 31, 2017. Since we will be a large accelerated filer, and we will cease to be an emerging growth company, as of December 31, 2018, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ending December 31, 2018. The rules governing the standards that must be met for management and our independent registered public accounting firm to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. In connection with our and our independent registered public accounting firm’s evaluations of our internal control over financial reporting, we may need to upgrade our systems, including information technology; implement additional financial and management controls, reporting systems, and procedures; and hire additional accounting and finance staff.

Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us or our independent registered public accounting firm conducted in connection with Section 404 of the Sarbanes-Oxley Act may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. Internal control deficiencies could also result in a restatement of our financial results in the future. We could become subject to stockholder or other third-party litigation, as well as investigations by the SEC, the stock exchange on which our securities are listed, or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions, payment of damages or other remedies. Further, any delay in compliance with the auditor attestation provisions of Section 404 could

Table of Contents

subject us to a variety of administrative sanctions, including ineligibility for short-form resale registration, action by the SEC and the suspension or delisting of our common stock, which could reduce the trading price of our common stock and could harm our business

Our credit facility contains covenants that restrict our business and financing activities, and the property that secures our obligations under the credit facility may be subject to foreclosure.

Our revolving credit facility contains a number of restrictions and covenants, which, among other things, restrict our ability to acquire or merge with another entity, dispose of our assets, make investments, loans or guarantees, incur additional indebtedness, create liens or other encumbrances, or pay dividends or make other distributions. The Credit Agreement also requires us to maintain compliance with a maximum leverage ratio and a minimum liquidity covenant. These provisions impose significant operating and financial restrictions on us and may limit our ability to compete effectively, take advantage of new business opportunities or take other actions that may be in our best interests. Our ability to obtain additional or other financing or to dispose of certain assets could also be negatively impacted because we have pledged substantially all of our assets as collateral in connection with the credit facility.

Our ability to comply with the provisions under the Credit Agreement may be affected by events beyond our control, and our inability to comply with any of these provisions could result in a default under the Credit Agreement. If such a default occurs, the lenders may elect to declare all borrowings outstanding, together with accrued interest and other fees, to be immediately due and payable, and they would have the right to terminate any commitments they have to provide further borrowings. If we are unable to repay outstanding borrowings when due, the lenders under the Credit Agreement also have the right to proceed against the collateral, including substantially all of our assets, granted to them to secure the indebtedness under that facility. If our indebtedness under the Credit Agreement were to be accelerated, we cannot assure you that our assets would be sufficient to repay in full that indebtedness. The occurrence of any of these events could have a material adverse effect on our business, financial condition, results of operations and liquidity.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

(a)

Issuances of Preferred Stock

None.

(b)

Issuances of Common Stock

None.

Use of Proceeds from Registered Securities

On August 2, 2016, we issued and sold 4,120,000 shares of our common stock in the initial public offering at a public offering price of $10.00 per share, for aggregate gross proceeds of $41.2 million. All of the shares issued and sold in the initial public offering were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No. 333-209115), which was declared effective by the SEC on July 27, 2016. The offering terminated on August 2, 2016.

The net offering proceeds to us, after deducting underwriting discounts of approximately $2.9 million and offering expenses paid by us totaling approximately $2.9 million, were approximately $35.4 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ~~10.0%~~10% or more of any class of our equity securities or to any other affiliates. We also paid $8.2 million in cumulative accrued dividends to our Series A preferred stockholders from the issuance proceeds.

Table of Contents

At ~~September~~June 30, ~~2017,~~2018, the net proceeds from our initial public offering were held in a diversified portfolio of bank deposits, government money market funds, government securities (U.S. Treasury and U.S. government agency securities), and high-grade short-term corporate bonds. All investments were in compliance with our Investment Policy and are highly liquid, with liquidity and capital preservation being the primary investment objectives. There has been no material change in our planned uses of the net proceeds from those described in the Prospectus dated July 27, 2016.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~None.~~On August 3, 2018, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association.

Our obligations under the Credit Agreement are secured by a security interest in substantially all of our assets and those of our subsidiaries and will also be guaranteed by our subsidiaries.

The foregoing description of the Credit Agreement and related guaranty and collateral agreements (the forms of which are included as exhibits to the Credit Agreement) does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement and exhibits, which are filed as Exhibit 10.1 to this report and hereby incorporated herein by reference.

Table of Contents

Item 6. Exhibits.

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.

2834

Table of Contents

EXHIBIT INDEX

Incorporated by Reference

Exhibit

File

Exhibit

Filed

Number

Description of Exhibit

Form

Number

Date of Filing

Number

Herewith

3.1

Fourth Amended and Restated Certificate of Incorporation

S-1

333-209115

06/09/2016

3.1

3.2

Amended and Restated By-laws

S-1

333-209115

05/06/2016

3.2

10.1

Credit Agreement, dated as of August 3, 2018, by and among Tactile Systems Technology, Inc., the lenders from time to time party thereto and, Wells Fargo Bank, National Association

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) / 15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) / 15d-14(a) of the Securities Exchange Act of 1934, as amended

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.1

The following condensed consolidated financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, formatted in XBRL: (i) Balance Sheets (unaudited), (ii) Statements of Operations (unaudited), (iii) Statements of Comprehensive Income (unaudited); (iv) Statements of Stockholders’ Equity (unaudited), (v) Statements of Cash Flows (unaudited), and (vi) Notes to the Condensed Consolidated Financial Statements.

~~EXHIBIT INDEX~~

Exhibit
Number

Description of Exhibit

Incorporated by Reference

Filed
Herewith




Form

File Number

Date of Filing

Exhibit
Number


3.1

Fourth Amended and Restated Certificate of Incorporation

S-1

333-209115

06/09/2016

3.1

3.2

Amended and Restated By-laws

S-1

333-209115

05/06/2016

3.2

4.1

Form of Senior Indenture

S-3

333-220132

08/23/2017

4.6

4.2

Form of Subordinated Indenture

S-3

333-220132

08/23/2017

4.7

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) / 15d-14(a) of the Securities Exchange Act of 1934, as amended

X

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) / 15d-14(a) of the Securities Exchange Act of 1934, as amended

X

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

X

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

X

101.1

The following condensed consolidated financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in XBRL: (i) Balance Sheets (unaudited), (ii) Statements of Operations (unaudited), (iii) Statements of Comprehensive Income (unaudited); (iv) Statements of Stockholders’ Equity (Deficit) (unaudited), (v) Statements of Cash Flows (unaudited), and (vi) Notes to the Condensed Consolidated Financial Statements.

X

2935

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Tactile Systems Technology, Inc.

Date: ~~November 7, 2017~~August 6, 2018	By:	/s/ Lynn L. Blake
		Lynn L. Blake
		Chief Financial Officer
		(Principal financial and accounting officer)

3036


	PART I—FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18 20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25 27
Item 4.	Controls and Procedures	26 28

	PART II—OTHER INFORMATION

Item 1.	Legal Proceedings	27 29
Item 1A.	Risk Factors	27 29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28 32
Item 3.	Defaults Upon Senior Securities	28 33
Item 4.	Mine Safety Disclosures	28 33
Item 5.	Other Information	28 33
Item 6.	Exhibits	28 34


												Retained		Accumulated
	Series B Preferred Stock			Series A Preferred Stock			Common Stock			Additional		Earnings		Other
										Paid-In		(Accumulated		Comprehensive		Treasury
(In thousands, except share data)	Shares	Amount		Shares	Amount		Shares	Par Value		Capital		Deficit)		Loss		Stock		Total
Balances, December 31, 2015	2,733,468	$	12,599	3,061,488	$	20,328	3,222,902	$	3	$	—	$	(5,652)	$	—	$	—	$	(5,649)
Stock-based compensation	—		—	—		—	—		—		902		—		—		—		902
Exercise of common stock options and warrants	—		—	—		—	234,135		1		223		—		—		—		224
Preferred stock dividends	—		436	—		811	—		—		(1,247)		—		—		—		(1,247)
Sale of common stock from initial public offering, net of offering expenses	—		—	—		—	4,120,000		4		35,378		—		—		—		35,382
Preferred stock dividends paid in cash	—		—	—		(8,207)	—		—		—		—		—		—		—
Common stock issued in lieu of series B preferred stock dividend	—		—	—		—	956,842		1		(1)		—		—		—		—
Conversion of series B preferred stock to common stock	(2,733,468)		(13,035)	—		—	2,733,468		3		13,032		—		—		—		13,035
Conversion of series A preferred stock to common stock	—		—	(3,061,488)		(12,932)	3,190,985		3		12,929		—		—		—		12,932
Common stock issued for series A & B preferred stock liquidation preference	—		—	—		—	2,354,323		2		(2)		—		—		—		—
Comprehensive income for the period	—		—	—		—	—		—		—		500		—		—		500
Balances, September 30, 2016	—	$	—	—	$	—	16,812,655	$	17	$	61,214	$	(5,152)	$	—	$	—	$	56,079

Balances, December 31, 2016	—	$	—	—	$	—	16,833,737	$	17	$	62,406	$	(2,773)	$	(11)	$	—	$	59,639
Stock-based compensation	—		—	—		—	—		—		3,104		—		—		—		3,104
Exercise of common stock options and warrants and vesting of restricted stock units	—		—	—		—	583,360		1		672		—		—		—		673
Taxes paid for net share settlement of restricted stock units	—		—	—		—	—		—		(278)		—		—		—		(278)
Common shares issued for employee stock purchase plan	—		—	—		—	259,981		—		2,210		—		—		—		2,210
Shares repurchased to cover taxes from restricted stock award vesting	—		—	—		—	(26,086)		—		—		—		—		(493)		(493)
Comprehensive income for the period	—		—	—		—	—		—		—		3,625		(7)		—		3,618
Balances, September 30, 2017	—	$	—	—	$	—	17,650,992	$	18	$	68,114	$	852	$	(18)	$	(493)	$	68,473


			Weighted
			Average Grant	Aggregate
	Units		Date Fair Value	Intrinsic
(In thousands except share and per share data)	Outstanding		Per Share	Value(1)
Balance at December 31, 2016	324,863	$	10.39	$	5,331
Granted	187,902		21.40
Vested	(75,821)		11.47
Cancelled	(35,887)		15.17
Balance at September 30, 2017	401,057	$	15.13	$	12,413

Deferred and unissued at September 30, 2017 (2)	1,912	$	21.51	$	59


	Fair Value Measurements at
	September 30, 2017 Using:
	Quoted Prices
	in Active		Significant
	Markets for		Other		Significant
	Identical		Observable		Unobservable
	Assets		Inputs		Inputs
(In thousands)	(Level 1)		(Level 2)		(Level 3)		Total
Recurring Fair Value Measurements:
Money market mutual funds	$	8,110	$	—	$	—	$	8,110
U.S. government and agency obligations		2,003		10,965		—		12,968
Corporate debt securities		—		9,025		—		9,025
Total	$	10,113	$	19,990	$	—	$	30,103